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ABSTRACT 
The effects of methamphetamine (Meth) in the periphery are not well studied and a 
comprehensive investigation on the effects and molecular mechanism will give insight 
into why Meth users are at an increased risk of infections. For this reason, we use 
macrophages as a model for the immune system dysregulation seen in Meth abusers 
and also because macrophages are a long-lived cell that HIV infects and persists in. We 
aimed to determine the effects of Meth on the cytokine production, histone modifying 
enzymes and the corresponding histone post-translational modifications, and the 
molecular mechanism in HIV-infected human macrophages treated with combination 
antiretroviral therapy. 
We measured a total of six histone deacetylases (HDACs) and found that Meth 
decreases HDAC1 but not in HIV or HIV and Meth. Combinational antiretroviral therapy 
also did not seem to have an effect on any HDACs measured. The decrease in HDAC1 
correlated to an increase in acetylation of HDAC1 histone targets, histone 4 lysine 5 and 
histone 3 lysine 18. Next, we determined that Meth induces a time-dependent and 
concentration dependent change in cytokine expression. Furthermore, Meth generated a 
rapid induction of pro-inflammatory cytokines at two hours and maintained until 6 hours 
post exposure. Subsequently, we expanded on where Meth could be affecting the TLR9 
signaling pathway to support the result of altered cytokine production by looking at DNA 
methylation, presence of transcription factors, and TLR9-mediated signaling mediators. 
In conclusion, Meth decreases HDAC1, modifies cytokine production in macrophages 
leading to a pro-inflammatory phenotype.  
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1.1. Brief History of Meth 
 
Methamphetamine hydrochloride (Meth), or crystal meth, was synthesized by a 
Japanese pharmacologist, Akira Ogata, in 1919 via reduction of ephedrine using red 
phosphorus and iodine [1]. Throughout the years, it was manufactured in pill form by 
pharmaceutical companies all over the world and had many names: Philopon (Japan), 
Pervitin (Germany), Obetrol (United States), and is still manufactured and prescribed as 
Desoxyn (United States) [2]. It has been prescribed for asthma and narcolepsy, and 
used as an alertness aid and an appetite suppressant to regulate weight [3]. The use of 
Meth skyrocketed during World War II when both the German and Japanese soldiers 
used it to enhance their performance and to prevent depression on the frontlines. The 
Japanese Kamikaze pilots also reportedly used it before suicide missions [4]. It was not 
until the 1960’s that the abuse worsened when doctors in California began administering 
an injectable form of Meth to treat heroin addicts [5]. Eventually, as the addictive 
qualities of the drug became apparent, governments began to regulate the production 
and distribution of prescription Meth more strictly. The United States made Meth a 
schedule II controlled substance under the Controlled Substances Act in 1970. Soon 
after the illicit underground the market for Meth grew, manufacturing of Meth starting in 
California and eventually moving eastward. In the Midwest rural areas Meth labs 
became popular because of the ease and accessibility of anhydrous ammonia tanks, an 
ingredient to needed to produce Meth. 
During the 1990’s and the early 2000’s, as illicit Meth manufacturing and abuse 
became endemic throughout the states, Meth research rose exponentially. Studies found 
it to be very dangerous and highly addictive compound, associated with permanent brain 
damage in long-term users [8, 9]. Furthermore, Meth use is correlated with an increase 
in mortality, as well as a dramatic rise in the violent crimes [10]. In addition, studies 
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found a positive correlation of Meth use with lowered sexual inhibitions and poor 
judgment, possibly contributing to the spread in transmission of Human Immunodefiency 
Virus type 1 (HIV-1) [11-13]. Due to the devastating effects of Meth on individuals and in 
the communities, Congress passed the Comprehensive Meth Control Act in 1996. This 
law regulated mail order and chemical companies selling precursor chemicals, such as 
red phosphorous, iodine and hydrochloric gas and required that companies show a 
legitimate use for the chemicals. The law also limited the quantity of the over-the-counter 
cold medications containing pseudoephedrine, another precursor chemical, and for the 
sale of these medications be a documented transaction. In conclusion, Meth is a very 
popular (over an estimated 1.4 million people used within the last year in the United 
States) and has become the drug of choice over other illicit psychostimultant drugs, 
including cocaine, heroin, and crack since Meth is cheaper and has longer lasting effects 
[14]. 
 
1.2. Chemistry of Meth 
 The chemical formula of Meth is C10H15N and its molecular weight 149.23 g/mol. 
It structurally similar to other abused drugs like amphetamine, ephedrine, and MDMA 
(ecstasy), as well as monoamine neurotransmitters like dopamine, epinephrine, and 
norepinephrine (Fig. 1.1.). Pharmacokinetic properties help explain how the body 
responds after Meth is administered and are measured by bioavailability (how easily the 
body absorbs a drug), volume of distribution (where in the body the drug will be located), 
and the half-life (how quickly half the dose is eliminated). Bioavailability, by definition, is 
the percentage of an administered non-metabolized drug that reaches the systemic 
system and therefore, 100% of a drug reaches the blood stream for intravenous doses. 




Figure 1.1. Similarities of chemical structures to methamphetamine 
 
The bioavailability. Meth has a high bioavailability regardless of ingestion route whether  
smoked (90.3%) or swallowed (67.2%) [15]. The volume of distribution (Vd) is a 
measurement of how much of the dose is in the tissues versus retained in the plasma. 
Drugs with low plasma binding capabilities have higher Vd and Meth has a moderate Vd 
of 5.8 L/kg for a 10 mg oral dose [16]. There are no known proteins that bind Meth in the 
plasma.The secondary amine group on Meth makes it more lipophilic, suggesting why 
Meth is distributed in tissues, including the brain, rather than the blood [17]. The last 
important property is half-life. The half-life is the amount of time it takes for the 
concentration of drug in blood plasma to reach one-half the original amount. The plasma 
half-life for Meth is an average of 12 h, significantly longer than cocaine which has half-
life of 90 min [15, 18]. Taken together these properties show that Meth is easily 




1.2. Cellular Mechanism of Meth Addiction 
Meth affects the regions of the central nervous system (CNS) that control 
judgment, reward-seeking behavior, and memory. Meth activates the prefrontal cortex, 
amygdala, and the nucleus accumbens [21, 22]. The prefrontal cortex is responsible for 
making decisions and cognition and innervates to the amygdala that is associated with 
emotional control and memory formation [22]. The nucleus accumbens processes the 
understanding of pleasure, reward, and reinforcing behaviors [23]. To this extent, these 
brain regions help elucidate the behavioral changes seen in Meth users like decreased 
inhibition, grandiosity, increased libido and ease of becoming addicted to the feeling of 
well-being. 
Figure 1.2. Dopamine Released as a Result of Natural Stimuli (Source: Di Chiara et 
al.) [24] 
The main cell type in the brain regions that affect Meth and addiction is 
dependent on dopaminergic neurons. Due the neurotoxicity of Meth, and a loss of  
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Figure 1.3. Dopamine Levels Released After Addictive Drugs Over Time (Source: Di 
Chiara et al.) [24] 
 
dopaminergic neurons, chronic users develop a tolerance to Meth. The increased 
tolerance makes users actively seek out higher doses (drug-seeking behavior), increase 
frequency of ingestion. The exact mechanism or mechanisms causing neurotoxicity from 
Meth is not known but many have been proposed, including inflammation, reactive 
oxygen species disrupting mitochondria function, disruption of the blood brain barrier, 
free radicals causing DNA damage, and/or glutamate toxicity [25-28]. Dopaminergic 
neurons are the main source of dopamine. Dopamine is a neurotransmitter released as 
a result of rewarding experiences such as food, sex, and natural stimuli (Fig. 1.2.). Meth 
releases magnitudes more dopamine than natural stimuli or other drugs making it very 
pleasurable and those feelings desired to be repeated by users and abusers [24] (Fig 
1.3.). Dopamine is a member of the catecholamine family and readily degraded in 
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neurons by enzymes such as monoamine oxidase and catechol-O-methyl transferase. 
Dopamine is naturally stored in vesicles until a stimulus induces its release. When Meth 
crosses the blood brain barrier and the cell membrane of neurons, it replaces the 
dopamine inside the vesicles [29]. Once dopamine is displaced, there is a higher 
concentration gradient inside the cytosol than outside the cell triggering an efflux of 
dopamine into the synaptic clefts [30]. Dopamine activating receptors on the post-
synapse in the brain regions mentioned previously propagates the chemical 
transmission and gives the effect of euphoria after Meth. The other cellular mechanism 
giving rise to the euphoria effect is the prolonged duration of dopamine in the clefts. 
Meth accomplishes this by inhibiting the reuptake of dopamine from the clefts by 
blocking the extracellular dopamine transporter on the exon terminals of the presynaptic 
neurons [31, 32]. Therefore, Meth is so addictive because it causes a large quantal 
release of dopamine for sustained periods of time.  
 
1.4. Health and Social Impact of Meth 
The physical effects of Meth are similar whether the drug is snorted, smoked, 
injected, or swallowed. The short term effects of Meth are due to the activation of 
sympathetic nervous system and are therefore, similar to the fight-or-fight responses, 
including increased wakefulness, decreased appetite, increased breathing, heart rate, 
and blood pressure [33]. Due to the lipophilic nature of Meth, Meth can pass through the 
placenta to the fetus and cause premature delivery, separation of the placenta from the 
uterus, low birth weight, and heart and brain problems in the child [34]. Long term effects 
of chronic Meth use include weight loss, kidney failure, brain damage, depression, 
hallucinations, permanent psychological problems, persistent ticks, violent and 
aggressive behavior, “meth mouth” or dental disease and teeth rot, insomnia, behavior 
resembling paranoid schizophrenia, increased susceptibility to infections, liver damage, 
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and stroke (because of increases in blood pressure, heart rate, and body temperature) 
[8, 35, 36]. Chronic use can damage the cardiovascular system, lungs, liver, and 
muscles [37-39]. Psychological addiction or dependence is when the user gets high to 
avoid the negative effects or withdraw symptoms of Meth include such symptoms as 
cravings, depression, irritability, shaking, and a loss of energy.  
Clearly, Meth has many short term and long term physical and psychological 
effects on the individual user but there are societal concerns and policies being set 
against the illegal use of Meth that have a huge monetary price. The social problems 
associated with Meth addiction come from crime and incarcerations, death, treatment 
facilities, and educational programs. In the most recent RAND study, the total economic 
cost of Meth is estimated at an average $23.4 billion [40]. Each estimate discussed will 
go further into detail of the actual break down included in the amount but will always 
have intangible cost and therefore, should be considered as a conservative estimate. 
Here, only the average cost will be reported, whereas the lower and upper limits are 
outlined in the study. 
In order to pay for their habit, addicts are tempted to rob, steal, or burglarize. This 
type of crime is just one category grouped under property damage and violent crimes. 
Another example of violent crimes committed by Meth abusers is physical violence. As 
mentioned previously, Meth use can lead to irritability, violent and aggressive behavior 
and according to one study Meth users reported violence against their partner, friends, 
family, or strangers at least once [41]. The other categories are arrests for Meth 
possession or sales and parole or probation revocation. More details contributing to the 
cost are the length of the prison sentence and cost associated per day per person and 
cost of drug testing of parolees. The best estimate for all of these expenses is $4.2 
billion, noticeably a huge portion of total economic cost of $23.4 billion.  
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A Meth related death is defined by the World Health Organization as a death 
caused by mental or behavioral disorders due to psychoactive substance use or 
poisoning of accidental, intentional, or undetermined intent. It is not just death but also 
injuries caused by Meth lab mishaps, chemical fires, and or hospitalization from 
inhalation of toxins from the ingredients of manufacturing Meth. Also, when explosions 
happen in the Meth labs there is a societal cost accompanying professionals to cleanup, 
process, properly dispose of chemical and hazardous waste. The cost of deaths was an 
average of $31.5 million and injuries added an additional $1 million while, the cost of 
cleaning up labs was $29.2 million. Yet, these estimates do not include the cost of 
pollution caused by the dumping, burying, or burning of the hazardous waste 
manufactured by each pound of Meth. Nor does the estimate include the cost of 
decontamination of individuals on the Meth lab sites or evacuation of nearby neighbors.  
Methamphetamine is a highly addictive drug and requires intense, long-term 
treatment. Treatment cost in the United States can be split between the community 
based treatment facilities (hospitals and specialty) and the federally provided treatment 
programs, which include Department of Defense, Veterans Affairs, Federal Bureau of 
Prisons, and IHS. The cost breakdown is $506 and $545 million for community based 
and federally provided treatment facilities, respectively [40]. According to the Alcohol and 
Drug Services Study, the average daily cost of inpatient treatment (community based 
facility) was about $76.13 per day in 2002, and the cost of outpatient treatment was 
about $26.72 per day [42]. Most private Meth rehab centers offer financing options for 
qualified patients or cost might be covered by insurance companies. Although, 
uncompensated treatment can place a huge burden on the national budget in the range 
of hundreds of millions of dollars [43].  
Education campaigns against the use of Meth significantly raises awareness of 
consequences and effects, influence users to use less Meth, and practice safe sex more 
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often in order to prevent sexually transmitted diseases [44]. And although, these 
marketing campaigns are less expensive and more cost-effective for raising awareness 
on important health and psychosocial issues than the cost associated with other 
methods, it is still costly to the public and government associations, between $20 million 
for one state and upper bounds of $448 million for the nation [40, 45].  
 
1.5. Effects of Meth on Innate Immunity 
Interestingly, Meth addicts are more susceptible to infections, including, HIV-1, 
Methicillin-resistant staphylococcus aureus (MRSA), genital herpes, fungal infections, 
and bacterial meningitis [46-50]. Infections are fought by the innate immune system, 
which is the rapid but non-specific first response to foreign pathogens and injuries in the 
body. There are many cell types that facilitate the innate immune response, among them 
macrophages are important because they are long-lived cells, harbor cryptoccal 
neoformans, facilitate fungal dissemination, and are an HIV reservoir [51]. Macrophages 
possess many functions to accomplish its role in both innate and adaptive immunity. In 
innate immunity, macrophages act as scavengers or surveyors of the surrounding tissue 
and rid the body of dead or dying cells and foreign particles by phagocytosis. In addition, 
macrophages have a critical role in initiating and regulating inflammation. Macrophages 
secrete cytokines and chemokines as a chemical signal to recruit other immune cells to 
the site of infection. Macrophages are the foremost cell type that process and present 
antigens, which plays a crucial role in initiating the adaptive immune response, or 
production of antibodies. After digesting a pathogen, a macrophage will present a part of 
the antigen to a corresponding T cell.  
Studies have demonstrated that Meth alters many functions of macrophages. 
Research on the effects of Meth on macrophage functions and their molecular 
mechanisms can help elucidate why Meth users are at an increased risk to infections, 
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hopefully leading to the development of immune boosting treatments that can offset the 
deleterious effects. Various studies show Meth alone alters cytokine production. For 
example, TNF-α, IL-8, IL-1β, MIP-1α (CCL3), MIP-1β (CCL4), IFN-α and other cytokines 
in monocyte-derived macrophages (MDM), THP-1 macrophages, and dendritic cells 
(another immune phagocyte) [50, 52-54]. It is not just cytokines that are altered but other 
small chemical signals are found to be decreased like nitric oxide and superoxide [46, 
55]. Another study showed that Meth reduces the ability of macrophages to rid the body 
of tumor cells compared to the stimulation of gram negative bacteria (LPS) and double 
stranded RNA viruses (poly I:C). Meth also decreased the expression of CD14, the co-
receptor for TLR4, which detects LPS. [55]. Moreover, Meth treatment decreases the 
ability of macrophages to clear HIV and worsens viral load in infected cells [56]. The 
mechanism of increased viral load was attributed to the down-regulation of anti-viral 
cytokine, IFN-α, and the increased expression of the HIV entry co-receptor, CCR5 in 
primary human MDM [50]. Lastly, Meth prevents the phagocytosis of Candida albicans 
and Cryptococcus neoformans, two major AIDS-related fungus pathogens [56, 57]. In 
conclusion, Meth is immunosuppressive by decreasing the ability of macrophages to 
respond normally to viruses, bacteria, and fungal infections. 
 
1.6. Effects of Meth on TLR Signaling 
 Since the discovery of the first mammalian toll-like receptor (TLR) in 1997, 11 
have now been identified in humans. Functional analysis of TLRs revealed that they 
recognize specific patterns or PAMPs (pathogen-associated molecular patterns) of 
microbial components and the homodimers or heterodimers of the receptors then 
activate specific signaling mechanisms. Although different TLRs recognize different 
PAMPs, a majority of the signaling pathways converge to a common factor, MyD88 




Figure 1.4. Mechanisms of Toll-like Receptors  
 
MyD88 contains a TIR (Toll/IL-1 receptor) domain in the C-terminal portion and a death 
domain at the N-terminal portion. The C-terminal domain of MyD88 associates with an 
activated TLR (referred to as TIRAP or TIR domain containing adaptor protein) while the 
death domain at the N-terminal of MyD88 recruits the linker protein IRAK (IL-1 receptor-
associated kinases) 1, 2 and 4. IRAK4 phosphorylates IRAK1, which in turn binds the 
TRAF (tumor-necrosis factor-receptor associated factor) domain of TRAF6 to IRAK1 and 
activates TRAF6. Ubiquitinated TRAF6 serves as a scaffold protein with TAK1 (TGF-β 
activated kinase 1) and TAB2 (TAK1- binding protein 2). TAK1 then couples to the IKK 
(inhibitor of NF-κB kinase) complex, which includes the scaffold protein NEMO (NF-κB 
essential modulator). Once TAK1 phosphorylates IKK, IKK phosphorylates the IκBα 
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protein (inhibitor of NF-κB alpha) and results in the dissociation of IκBα from NF-κB 
allowing NF-κB to translocate to the nucleus and mediate an increase in inflammatory 
cytokine genes such as TNF-α, IL-1 and IL-12 [58-61]. 
 The effects of Meth on macrophage function, especially altered cytokine 
production and decreased defense against bacterial and viral infections, have been 
implicated to be a consequence of deregulated TLR signaling. One such study showed 
that activation of TLR9 by its agonist CpG ODN up-regulates the expression of TLR9, 
IFN-α, IRF-7, and MyD88. These anti-viral factors boost the immune response and 
reduce the HIV viral load in macrophages in vitro. However, METH treatment of 
macrophages greatly inhibited the anti-HIV effect mediated by TLR9 signaling by 
inhibiting the expression of TLR9 and downstream signaling factors [62]. Upon activation 
of TLR4 with LPS, that Meth exacerbated the TNF-α mRNA expression and protein 
levels however, in conjunction with an IKK inhibitor TNF-α levels decreased suggesting 
the common pathway of MyD88-dependent signaling in Meth-induced effects [63]. Taken 
together, further studies need to be conducted to determine the molecular mechanism of 
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2.1.1. Toll-like receptor signaling in macrophages 
Macrophages are key elements of the innate immune system that rapidly respond to 
various stimuli such as bacterial, viral, fungal or parasitic infections, tissue injury as well as other 
insults. Macrophages detect viral and bacterial infections by utilizing Toll-like Receptors (TLRs). 
TLRs 1, 2, and 4 are expressed on the cell surface and detect bacterial components like 
lipopolysaccharide (LPS), whereas intracellular TLRs 3, and 7-9 sense viral RNA and DNA. TLR 
signaling consists of two pathways, the MyD88-dependent and MyD88-independent pathways. 
The MyD88-independent pathway leads to the activation of IRF3 (interferon regulatory factors 
3) and IRF7 to induce Type I interferons. In the MyD88-dependent TLR signaling pathway, 
MyD88 (myeloid differentiation primary response gene 88) recruits IRAK4 (IL-1 receptor-
associated kinase 4) and activates IRAK1. Activated IRAK1 interacts with TRAF6 (TNF-receptor 
associated factor 6) to activate TGF-β–activated kinase 1 (TAK1). The TAK1-TRAF6 complex 
simultaneously phosphorylates and polyubiquitinates IKK (I kappa B kinase). Post-translational 
modifications of IKK relieve inhibition of NF-κB (nuclear factor kappa-light-chain-enhancer of 
activated B cells) and allow NF-κB to translocate to the nucleus and regulate the production of 
pro-inflammatory cytokines and chemokines [1]. If TLR signaling is impaired, the host becomes 
susceptible to an invading microorganism by failing to recruit other immune cells and not 
eliciting the proper adaptive immune response.  
2.1.2. Epidemiology of Meth and opportunistic infections 
Methamphetamine (Meth) is one of the most addictive and destructive illicit drugs and 
its use is on the rise [2].  Epidemiology data demonstrates that chronic Meth users are at an 
increased risk of acquiring infections such as Methicillin Resistant Staphylococcus aureus (MRSA) 
and HIV-1 [3-5]. Moreover, in vivo and in vitro studies show histoplasmosis, cryptococcal 
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neoformans, HIV-1, as well as other sexually transmitted infections, tend to progress more 
rapidly with the use of Meth [6-11]. This suggests that Meth has the ability to profoundly 
interfere with the cell-mediated immune response. However there remains a lack of 
understanding as to how Meth impairs immune cell function at the molecular level. 
2.1.3. Delineating the mechanism of Meth-exposed macrophages 
It has been shown in macrophages that Meth exacerbates LPS-mediated expression of 
IL-8, TNF-α and IL-1β mediated by p38 MAPK and PI3-AKT signaling pathways  [12]. Other 
studies show that phagocytosis, antigen processing, and antigen presenting in macrophages is 
diminished by Meth exposure [13]. These studies indicate that Meth exposure impairs 
macrophage functions; however the exact mechanism is unknown. Several possibilities include 
alterations in signaling mediators, transcriptional factors, histone post-translational 
modifications and DNA methylation [13, 14]. In this study, we investigated how exposure to 
Meth affects macrophage cytokine production and subsequent observations of the impairment 
of cytokine responses due to TLR9 signaling by recognition of DNA.  
 
2.2. Materials and Methods 
2.2.1. Cell culture and treatments 
THP-1 monocytes, a human monocytic cell line derived from an acute monocytic 
leukemia patient, were obtained from ATCC (Manassas, VA), and plated at a concentration of 
106 cells per mL. They were differentiated into macrophages in the presence of 200 nM phorbol 
12-myristate 13-acetate (PMA, Sigma-Aldrich; St. Louis, MO) in complete media, which consisted 
of RPMI-1640 medium (HyClone; Logan, UT) supplemented with 10% fetal bovine serum 
(Atlanta Biologicals; Norcross, GA) and 50 µM of beta-mercaptoethanol (Gibco; Grand Island, 
NY). All of the media was exchanged every other day for four days and cells were allowed to rest 
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in complete media without PMA for an additional two days, at which point cells assumed a 
macrophage-like phenotype (Fig. 2.1). On day six, media was either replaced with 100 µM 
methamphetamine (Sigma-Aldrich) in complete media or control media for the specified times. 
In a separate series of experiments macrophages were treated with either 1µg/mL of mock CpG 
oligodeoxynucleotides 2243 (CpG ODN) or TLR9-stimulatory CpG ODN 2216 (both from 
Invivogen; San Diego, CA) for specified times. 
2.2.2. Cell viability assay 
Both time-dependent and concentration-dependent experiments on the viability of THP-
1 macrophages were performed according to the MTT assay protocol. Macrophages were 
seeded onto 96-well plates at a density of 5 × 104 cells/well and treated with 0, 1, 10, 100, 500, 
and 1000 µM methamphetamine for two hours. In parallel experiments cells were seeded at the 
same density and propagated for 2, 6, 24, and 48 hours of 100 µM Meth along with the 
appropriate time control (RPMI media). Positive and negative controls consisted of 100% killed 
macrophages or wells with only MTT reagent, respectively. The positive control macrophages 
were treated with 1% Triton X-100 (Fisher Scientific; Fair Lawn, NJ) to permeabilize the cell 
membrane. The cell viability was assessed using the MTT assay (Life Technologies; Carlsbad, CA). 
Absorbance at 490 nm was quantitated using a SpectraMax M3 microplate reader (Molecular 
Devices, Sunnyvale; CA, USA). Eight parallel replicates were measured for each condition. 
2.2.3. Human cytokines and chemokines RNA PCR array 
Total RNA was extracted using Trizol (Life Technologies) and cleaned using the RNeasy 
Mini Kit according to manufacturer’s protocol (Qiagen; Germantown, MD). Only RNA that had a 
260/280 ratio greater than 1.8 and a RIN value greater than 7 was used for reverse transcription 
(RT) to synthesize cDNA using the RT2 First Strand Kit (SABioscience; Frederick, MD). Reverse 
transcription and PCR was executed by following the SABioscience’s protocol with a total of 5 µg 
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of RNA being reverse transcribed and DNA contamination eliminated by incubating with 
genomic DNA elimination mix supplied by the manufacturer. RNA was converted to cDNA using 
the RT Cocktail mixed with the DNA-free samples and incubated at 42ºC for 15 min followed by 
heating at 95ºC for 5 minutes. Samples were diluted with the 2X RT2 SYBR Green Mastermix 
before performing PCR on the Applied Biosystems StepOnePlus Real-Time PCR System using the 
default settings. Every sample was loaded in triplicate by the fully automated Corbett Robotics 
(San Francisco, CA) to provide uniformity across all plates. Relative abundance was calculated 
using the comparative CT method [16]. 
2.2.4. RNA extraction and quantitative PCR 
Cells were lysed directly in the culture dish with Trizol Reagent (Life Technologies). RNA 
was resuspended in 10 mM Tris (Pro-Pure, Solon, OH) and 1 mM EDTA (Fisher Scientific), pH 8.0 
in RNase free water. One microgram of RNA was converted to cDNA using the High Capacity 
cDNA Reverse Transcription Kit (Life Technologies) per the manufacturer’s protocol. The primers 
used to detect IL-8, TNF-α, CCL7, CXCL1, IFN-α, and TLR9 were purchased from Integrated DNA 
Technologies (Coralville, IA); human GAPDH primers were obtained from Applied Biosystems 
(Warrington, UK). The relative abundance of each gene was calculated using the comparative CT 
method [15]. 
2.2.5. Harvest and protein extraction 
THP-1 macrophages were washed thrice with phosphate-buffered saline (PBS, HyClone), 
and collected for either protein or RNA. To obtain protein from whole cell lysates, cells were 
scraped in PBS and pelleted by centrifugation at 1000 x g for 5 min at 4°C and re-suspended in 
300 µL per 106 cells of lysis buffer. Lysis buffer contained 2% (w/v) SDS (Bio-Rad; Hercules, CA), 
in 0.1 M Tris-HCl (Fisher Scientific), 0.1 M DTT (Promega; Madison, WI) and 1X Protease Inhibitor 
Cocktail (Sigma-Aldrich). Cells were heated at 95°C for 5 min, allowed to cool, and 100 units/mL 
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Benzonase Nuclease (Merck KGaA; Darmstadt, Germany) were added. Protein was quantified 
using Pierce 660 Assay as per the manufacturer’s protocol using 50 mM ionic detergent 
compatible reagent (Thermo Scientific; Rockford, IL). Twenty micrograms of whole cell lysate 
from each condition were loaded onto a 4-12% bis-tris gel (Life Technologies) and separated at 
100 V for 90 min and transferred to a PVDF membrane at 25 V for 90 min. Membranes were 
blotted with antibodies recognizing the following antigens: NF-κB/p65 [Cat# 8242] (New England 
Biolabs, Ipswich, MA), TLR9 [Cat# ab85860] (Abcam, Cambridge, United Kingdom), and IRAK1 
[Cat# ab238] (Abcam) all at 1:1000 concentration overnight in 4°C. 
2.2.6. Immunocytochemistry 
THP-1 cells were plated and differentiated as described above. Methamphetamine and 
CpG ODN treatment was for 2 hours on day 6 post-plating. Macrophages were washed three 
times with PBS (HyClone), scraped, pelleted and resuspended in PBS to obtain a final 
concentration of 1x105 cells per ml for cytospin. After cells were spun at 1000 rpm for 10 min on 
glass microscope slides, cells were fixed to the slide with 4% paraformaldehyde (Sigma-Aldrich) 
at room temperature for 30 min and rinsed once with PBS. Cells were blocked and 
permeabilized simultaneously by using 0.5% Tween 20 (Fisher Scientific) in PBS (PBST) 
supplemented with 10% normal goat serum (Invitrogen; Carlsbad, CA) for one hour at room 
temperature and rinsed once with PBST. Slides were stained with TLR9 [Cat# Ab85860] (Abcam) 
at 1:500 for 1 hour and rinsed three times with PBST for 5 min each before secondary antibody 
was added at a concentration of 1:500 for 45 min at room temperature in the dark. Slides were 
washed three times in PBST to remove secondary antibody and incubated with 1 µg/mL of DAPI 
(Invitrogen) for 5 min. After one wash, one drop of Prolong Gold (Invitrogen) was added and a 
cover slip was placed over cells prior to being visualized using Zeizz Axio Observer inverted 
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microscope at 40X oil immersion and capturing images using AxioVision Release software 
version 4.8. 
2.2.7. Methylation pyrosequencing 
DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen) according to 
manufacturer’s protocol. Samples were treated with mock CpG, Meth, or Meth and CpG as 
previously mentioned in Cell Culture and Treatments. Bisulfite treatment was carried out using 
1000 ng of sample genomic DNA and the EZ DNA Methylation-Direct kit (Zymo Research, 
Orange, CA). This process deaminates unmethylated cytosine residues to uracil leaving 
methylated cytosine residues unchanged. To perform PCR reactions, 42 ng of bisulfite-modified 
DNA was used as template. The PCR reactions were performed in a total volume of 50 µl for 35 
cycles using Roche Diagnostic Corporation (Indianapolis, IN) FastStart Taq DNA Polymerase 
(1.0U), MgCl2 solution (3.5 mM), dNTP’s (0.2 mM), sense primer (0.24 µM), antisense primer 
(0.18 µM), with denaturation at 95 ºC for 30 seconds, annealing temperature for 45 seconds at 
annealing temperatures specific to the primer and extension at 72 ºC for 1 minute (Table 2.1). 
For a positive (high methylation level) control, Roche Diagnostic Corporation (Indianapolis, IN) 
human lymphocyte genomic DNA was methylated using M. SssI (CpG) methylase kit (New 
England Biolabs, Ipswich, MA). Methylated DNA (1000 ng) was treated with sodium bisulfite as 
described above. Sodium bisulfite treated Roche human lymphocyte genomic DNA (1000 ng) 
served as a negative (low methylation level) control.  All PCR products were electrophoresed on 
0.8% agarose gel, stained with ethidium bromide, and visualized for appropriate and pure 
product before proceeding with all analyses using a Bio-Rad Laboratories (Hercules, CA) Gel-Doc 
UV illuminator. Methylation percentage of each CpG was determined using a Qiagen (Valencia, 
CA) Pyromark Q96 pyrosequencer and sequencing primer according to manufacturer’s 




2.3.1. Meth exposure affects the mRNA expression profile of cytokines and 
chemokines 
Macrophages were exposed to 100 μM Meth for 2, 6, or 24 h and profiled for a broad set 
of 84 immune mediators including cytokines, chemokines, interleukins and growth factors. An 
RT kit was optimized for the downstream real-time PCR-based gene expression analysis with the 
Human Cytokine and Chemokine RT² Profiler PCR Arrays (SABiosciences), which is a 96-well 
plate format that includes 84 immune mediators and the appropriate controls. The mRNA 
expression profile resulted in identification of 58 differentially expressed mediators with more 
than two-fold up or down regulation in at least one time point (Table 2.3). Meth elicited a strong 
(more than 10-fold) up-regulation of CXCL16 and CXCL2, a moderate (5- to 10-fold) up-
regulation of IL-7, CCL20, CXCL1, CCL24, and IL-8, and a strong (more than 10-fold) down-
regulation of CCL7 (also called monocyte-specific chemokine 3 (MCP-3) at the 2 h time point. 
TNF-α maintained moderate transcript levels at 2 and 6 h of Meth exposure. In addition, IL-10 
became highly up-regulated at 6 h. Similarly, CXCL13 was up-regulated between 6 h and 24 h. 
Some cytokine responses to Meth exposure were dynamic. For example, while CXCL16 was 
strongly up-regulated at 2 h of exposure, at the 6 h time point the levels subsided back to 
control level. Notably, by 24 h the majority of the cytokines returned back to control levels. In 
accordance with previous studies, we performed viability assays of Meth-treated macrophages 
for up to 48 h (Fig. 2.2). There was a slight trend of decreased viability however, we did not 




2.3.2. Meth promotes a pro-inflammatory macrophage phenotype 
Based on the classification of pro-inflammatory and anti-inflammatory functions of 
cytokines, the pattern of cytokine expression after Meth exposure shifted the phenotype of 
macrophages towards pro-inflammatory (Fig. 2.3) [16-18]. Overall, the changes in cytokines 
expression peaked at 2 h after exposure to a single dose of Meth and persisted for 6 h, 
eventually subsiding by 24 h (Table 2.3). Next, we focused our study on TNF, CXCL1 and IL-8. 
Each was up-regulated in an increasing manner at stepwise concentrations of Meth (Fig. 2.4). 
The effect of Meth at higher concentrations such as 500 μM or 1 mM, was masked, possibly due 
to a small yet significant decrease in cell viability, which was not observed in concentrations up 
to 100 μM (Fig. 2.2). Therefore, to prevent the cytotoxic effects of Meth and cytokine-induced 
cytokine expression, all further experiments were conducted at 2 h of Meth exposure at 100 
µM.  
2.3.3. Meth down-regulates CCL7 expression 
Based on our array results showing a robust down-regulation of CCL7 by Meth and given 
the importance of CCL7 in innate immunity we further looked at signaling pathway upstream of 
CCL7 expression [13, 21]. CCL7 is induced by TLR9 activation in a MyD88-dependent pathway 
and utilizes AP-1 and NF-κB as transcription factors [21]. First, to confirm the array data we 
performed RT-qPCR to investigate whether CCL7 is down-regulated by Meth exposure in a 
concentration dependent manner. Indeed, increased concentrations of Meth from 1 to 100 μM 
at 2 h of exposure led to a statistically significant reduction in CCL7 mRNA expression (Fig. 2.5 
A). It has been shown in vivo that the expression of CCL7 and INF-α is dependent on activation of 
TLR9 [21]. Therefore, we performed experiments to see if Meth would block TLR9 mediated 
signaling. To do this we used CpG ODN, an agonist of TLR9, which is also used as a surrogate for 
an infection model of bacterial DNA. We measured the expression of CCL7 in the presence of 
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Meth and CpG ODN for 2 h, and used INF-α as a positive control. As expected, treatment with 
the TLR9 agonist (CpG ODN) up-regulated expression of CCL7 and IFN-α. CCL7 was down-
regulated when macrophages were treated with only Meth, at similar levels to our time-
dependent profiling experiment. Meth also attenuated the CpG ODN-induced expression of 
both, CCL7 and IFN-α (Fig. 2.5 B-C).  
2.3.4. Meth affects TLR9 signaling pathway 
The attenuation of CCL7 and IFN-α expression by Meth during TLR9 activation suggested 
that Meth reduces viral defense. CCL7 and IFN-α utilize several of the same signaling 
components downstream of TLR9, but the expression of each is dependent on different 
transcription factors, NF-κB and IRF7 respectively [22, 23]. Thus, we hypothesized that in order 
for both CCL7 and IFN-α to be differently expressed, the inhibition caused by Meth was 
occurring at or upstream the common TRAF3/6 signaling factors that are used by both cytokines 
(Fig. 2.8.). First we investigated if the levels of TLR9 changed upon Meth exposure. Neither 
mRNA expression nor protein levels of TLR9 were significantly changed compared to mock CpG 
treatment, but there was a trend of reduced TLR9 expression after Meth treatment alone (Fig. 
2.6). Meth did, however, decrease the expression of TLR9 in CpG ODN treated cells to the level 
of control cells. 
2.3.5. Effect of Meth on the transcriptional regulator NF-κB 
There are several putative binding sites in the promoter region of CCL7 for the 
transcription factors, AP-1 and NF-κB. A possible mechanism of how Meth down-regulates the 
expression of CCL7 is Meth reduces the abundance of the transcription factors for CCL7. 
Therefore, we measured the protein levels of the NF-κB subunit, p65, from Meth exposed 
macrophages up to 48 h and observed no change over time (Fig. 2.7). Although these results 
informed us that overall levels of NF-κB do not change in Meth treated cells, it could still 
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interfere by preventing the translocation of NF-κB and making it less available at the promoter. 
The nuclear localization signal of NF-κB is masked by IκB and the inhibition of NF-κB by IκB is 
released when IκB is phosphorylated and degraded. Meth preventing the phosphorylation or the 
degradation of IκB warrants further investigation as well as the availability of the other CCL7 
transcription factor, AP-1.  
2.3.6. DNA methylation in the promoter region of CCL7 does not contribute to 
suppression 
Changes in DNA methylation might be one potential mechanism that Meth induces to 
alter gene expression. To investigate whether such a mechanism is occuring on CCL7 expression, 
we measured the DNA methylation status of two CpG islands in the promoter region of CCL7. 
These islands are located on chromosome 17:(hg19) at positions 32596886 and 325971103. One 
CpG island is located at -349 relative to the promoter start site while second one is located at 
position -132. We have found that in mock treated macrophages for 2 h at the -349 position is 
hypermethylated at the level of 96% while -132 position is hypomethylated at the level of 2% 
(Table 2.2). The levels of methylation of both CpG islands were not affected by addition of Meth 









Table 2.1. Parameters for DNA pyrosequencing. Primers for CCL7 around two CpG 
islands (CCL7-1 and CCL7-2), the size of the PCR product, and optimal annealing 
temperature.  
  
Gene Sense Primer (5’ to 3’) 
Anti-sense Primer  
(5’ to 3’) 
Sequencing Primer   

























Table 2.2. Percentage of methylated DNA around both CpG islands for CCL7 
promoter. Macrophages were either mock treated with 1 µg/mL of non-stimulatory CpG 
(ODN 2243), 100 µM of methamphetamine, or 1 µg/mL of stimulatory CpG (ODN 2216)  
for two hours. Then harvested for DNA and analyzed for methylation. Sss1 methylated 






Table 2.3. RNA expression profile of immune mediators over time from Meth-
exposed macrophages. RT-qPCR analysis of mediators that illicit an immune response 
including receptors, growth factors, interleukins, and cytokines were measured after 
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macrophages were exposed to Meth for either 2, 6, or 24 hours. The average fold 
change represented in each box is from Meth treated macrophages relative to 
corresponding time control from 3 biological replicates. Red positive box indicates an up-
regulation while a green negative box indicates a down-regulated gene. Fold changes 






Figure 2.1. THP-1 monocyte to macrophage differentiation. THP-1 monocytes, a 
human monocytic leukemia cell line, were differentiated according to ATCC guidelines 
with 200 nM of PMA on days 0 and 2 until day 4. Cells rest in PMA-free media from day 
4 to 6, after which they are considered macrophage-like and exposed to treatments. 
Similar to in-vivo macrophages, THP-1 macrophages are terminally differentiated and do 
not proliferate. 10X objective. Arrowhead ( ) symbolize spherical, round monocytes. 






Figure 2.2. Viability of macrophages at different times and concentrations of Meth 
exposure. (a) Macrophages treated with either control (complete RPMI media) or 100 
µM of Meth for 2, 6, 24, and 48 hours. Viability assessed by MTT assay and normalized 
to the respective time control and to a positive control. (b) Macrophages were treated 
with varying concentrations of Meth (1-1000 µM) for 2 h. Viability assessed by MTT 
assay and normalized to control (0 µM). Positive control cells were treated with 1% 
Triton X-100. Data are represented as the mean ± SD. An asterisk (*) indicates p<0.05 






Figure 2.3. Characterization of immune mediators from Meth-exposed 
macrophages. Macrophages were treated with 100 µM Meth for either 2 or 6 h. After 
treatment, total RNA was isolated and expression of chemokines, interluekins, and 
cytokines was profiled by RT-qPCR. Cytokines are defined as either pro-inflammatory 
(a, c) or anti-inflammatory (b, d) and organized in decreasing order of regulation levels. 






Figure 2.4. Concentration dependence on mRNA cytokine expression. 
Macrophages were exposed to 0-100 µM methamphetamine for 2 h and select cytokines 
were chosen for relative quantification by RT-qPCR. Baseline expression of each 
cytokine corresponds to control (0 µM) and represents a fold expression of 1. Data are 
represented as the mean±SD fold expression of 3 independent experiments. An asterisk 
(*) indicates p<0.05 by a Student’s t-test. All fold change is normalized to the 











Figure 2.5. Methamphetamine inhibits the expression of CCL7. (a) RNA expression 
of CCL7 was measured by RT-qPCR in macrophages treated with varying 
concentrations of methamphetamine (0-100 µM) for 2 h. (b, c) Macrophages were 
exposed to 100 µM or 1 µg/mL CpG (CpG oligodeoxynucleotides) for 2 h. Expression of 
IFN-α is induced by activation of TLR9 by CpG and used as a positive control. Data are 
represented as the mean±SD fold expression of 3 independent experiments. An asterisk 
(*) indicates p<0.05 by a Student’s t-test. Fold changes are normalized to the 






Figure 2.6. Methamphetamine attenuates the CpG-induced expression of TLR9. (a) 
Representative image of immunocytostained macrophages for TLR9 (green) at 1:500 
and DAPI (blue) at 1 µg/mL that were either mock treated with 1 µg/mL non-stimulatory 
CpG (ODN 2243), 100 µM of methamphetamine, or 1 µg/mL of stimulatory CpG (ODN 
2216) for 2 h. 40X oil immersion fluorescent microscope (b) Immunostaining for TLR9 
antibody protein were quantified using Image J. Data are represented as the mean±SD 
fluorescent intensity per area of 3 independent experiments. (c) Total RNA from treated 
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macrophages was converted to cDNA and the levels of TLR9 determined by RT-qPCR 
relative to the mock treated macrophages. An asterisk (*) indicates p<0.05 by a 






Figure 2.7. Methamphetamine does not alter protein levels of the pro-inflammatory 
transcription factor, NF-κB. Macrophages were either mock treated (RPMI media) or 
treated with 100 µM methamphetamine for 1, 2, 6, and 24 h. Western blots from whole 
cell lysates were blotted for anti- p65 (1:1000) or anti-actin (1:2000) for a loading control. 






Figure 2.8. Signaling pathway of TLR9 by CpG activation and summary of results. 
Single stranded unmethylated CpG (cytosine phosphate guanine) is endocytosed and 
stimulates TLR9 (Toll-like receptor 9) signaling. Macrophages were treated with CpG or 
Meth and CpG for two hours. Numbers in this figure indicate a description for each 
experiment. (1) TLR9 mRNA and protein was up-regulated after CpG treatment. (2) 
Meth decreased the CpG induction of TLR9 back to control levels. (3) Activation of TLR9 
in combination with an IRAK1/4 chemical inhibitor leads to the inhibition of CCL7 
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transcription. Although it shows that the regulation of CCL7 is utilizing IRAK1/4 as 
intermediate, we found no evidence of Meth effecting the overall protein expression of 
IRAK1 or the phosphorylation of IRAK1 at Thr387. (4) Total levels of IkB protein did not 
decrease after 1 hour of Meth exposure nor up to 24 hours. This, however, was similar 
to other studies where degradation of IkB was found as early as 15 min for certain 
treatments. (5) Meth does not change the overall levels of NF-κB in the cell over time, 
however one possibility is that Meth prevents the translocation of NF-κB thus making it 
less available at the promoter. (6) CpG treatment moderately (5-10 fold) up-regulated 
the expression of CCL7 and IFN-α when compared to mock treatment. (7) Yet, Meth and 
CpG together down-regulated both cytokines. (8) Pyrosequencing results of either 
treatment, CpG or CpG and Meth, showed no change in DNA methylation at either CpG 






The effects of Meth could be acting on the extracellular receptors, intracellular signaling 
molecules, or in the nucleus. We focused these studies on one signaling pathway, the MyD88-
mediated TLR9 signaling pathway. The investigation started at the utmost upstream location, 
examining changes in the TLR9 mRNA expression and protein levels. The effects of Meth in 
conjunction with CpG treatment can be seen in red circles whereas the remaining is of the 
effects of CpG alone (Fig. 2.8). First, a small down-regulation of TLR9 by Meth was observed. 
However, it was not sufficient to explain the strong down-regulation of CCL7 and INF-α. This 
suggested that Meth was affecting signaling mediators or transcription regulation further 
downstream of TLR9. Therefore, we measured protein of signaling factors such as IRAK1, IκB and 
IRF7 but found no changes in total levels or phosphorylation at key regulatory sites (data not 
shown). Next, we found that Meth does not affect the expression of a key transcription factor, 
NF-κB. Furthermore, the levels of DNA methylation in the promoter region of CCL7 did not 
change in the presence of Meth and or CpG treatment. Hence, we might expect to see either an 
absence of enhancing transcriptional complexes or an increase in the silencing transcriptional 
complexes found around the CCL7 start site. To measure the changes in either the silencing or 
enhancing transcription complexes, we would first use chromatin immunoprecipitation (ChIP) 
for either NF-κB or AP-1 transcription factors and PCR for CCL7. Next, use a mass spectrometry 
approach to identify the differences in Meth exposed macrophages to control treated cells from 
the ChIP pull down. The exact mechanism of how Meth affects TLR9 or other MyD88-mediated 
signaling pathways will require more extensive studies. 
Macrophages respond rapidly to external stimuli and one such response is the release of 
cytokines, which plays a critical role in recruiting other immune cells to initiate the innate and 
adaptive immune response. Changes in the production of cytokines can have autocrine and 
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paracrine signaling effects as well as, can determine activation and phenotypic polarization of 
these cells. Generally, polarized macrophages can be classified as an M1, classically activated 
macrophage or M2, alternatively activated macrophage however, there is a spectrum of 
activation states in between these two [25, 26]. Thus, the phenotype of macrophage activation 
under specific pathological condition or stimulation will be best described by profiling cytokine 
secretion among other factors [27]. Classically activated (M1) macrophages will be polarized in 
response to stimulation by IFN-γ and LPS and characterized by their ability to secrete pro-
inflammatory cytokines such as TNF-α, IL-1β, and IL-12 [28, 29]. On the other hand, the M2 
phenotype, which includes the M2b phenotype, is considered immune regulating by expressing 
high levels of IL-10, CXCL1, and TNF-α and can be induced by TLR ligands [30]. Based on our 
results, the mRNA profile of cytokine expression in macrophages exposed to Meth most closely 
fit an M2b phenotype, more so than other types. However, additional cell surface markers and 
other chemical molecules are needed to completely characterize the phenotype of Meth-
exposed macrophage.  
One principal finding of the present study is that Meth induces the up-regulation of pro-
inflammatory cytokines (Fig. 2.3).The pro-inflammatory effect of Meth has been previously 
demonstrated in literature by measuring a few pro-inflammatory cytokines like TNF-α, IL-1β, 
and IL-8; however this is the first study profiling 84 cytokines and chemokines as a systematic 
study [12, 19, 20]. Also, these studies were focused on the LPS-induced response mimicking 
bacterial infection and were limited in scope by the number of cytokines measured [12, 31]. 
Therefore, in our study we profiled 84 cytokines and chemokines, which provided a more 
comprehensive overview of macrophage polarization. Indeed our results showed that besides IL-
10 and the modest expression of three others (CCL19, CCL21, and IL-4), macrophages showed 
pro-inflammatory phenotype over a 24 hour time frame of Meth exposure. One of most striking 
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observations resulting from profiling the cytokines over time was the strong down-regulation of 
CCL7 within 2 hours of Meth treatment indicating TLR9 signaling as a target pathway for this 
suppression [21]. This notion was reinforced further by our observations that Meth also 
suppresses the expression of IFN-α upon CpG ODN treatment. The CCL7 response was time- and 
concentration-dependent and, as anticipated, the onset of the Meth effect is rapid in 
macrophages.  
Many of the pro-inflammatory cytokines such as TNF-α, IL-8, IL-1, and CXCL1 are 
regulated by NF-κB. In particular, IL-6 and IL-8 expression after Meth have been investigated for 
the dependence on NF–κB in other model systems. In these experiments, Meth up-regulated IL-
8 and IL-6 in astrocyte cell line after 3 days of exposure [32]. The subcellular protein levels of NF-
κB was measured over a span of 6 hours and, as expected to induce IL-8 and IL-6, was found to 
translocate to the nucleus. The authors also reported that PI3K/Akt, which is upstream of the 
activation of NF-κB, is involved in the Meth-induced expression of IL-6 and IL-8. In a similar study 
using gp120 transfected astrocytes, Meth was found to synergistically increase IL-6 and IL-8 
mRNA and protein [33]. In our study, we found a concentration dependence effect of Meth on 
IL-8 but we did not measure IL-6 since it was not found statistically significant in the initial mRNA 
screening of time-dependent Meth exposed macrophages. Overall, the induction of cytokines is 
initiated by multiple pathways depending on the stimulus and even overlap by using the same 
signaling factors in different pathways thus, adding to the complexity of delineating the pathway 
for Meth-induced alterations of cytokine expression. 
Since Meth users show increased susceptibility to various infections, we posit that the 
TLR signaling pathways, which orchestrate the clearance of infections, is hindered under Meth 
exposure [1, 34]. The significance of our results is further reinforced by previous studies showing 
that the expression of CCL7 is critical for immunity against cryptococcosis [7, 21]. While 
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infections with this fungus are rarely seen in those with fully functioning immune systems, it is 
the most common cause of fungal meningitis in AIDS patients, killing more than half a million 
people worldwide per year [35]. After the fungi, cryptococcus neoformans, are phagocytosed by 
alveolar macrophages it disseminates from the lungs to other parts of the body, including the 
brain regions to give rise to fungal encephalitis and meningitis [36]. Thus, the Meth-induced 
inhibition of CCL7 would prevent the recruitment of monocytes and eosinophils that facilitate 
the clearance of the fungal infection [21].  
In summary, we conclude that Meth is immunosuppressive and inhibits TLR9 signaling 
and CCL7 and IFN-α expression. The cytokine environment produced by the Meth-exposed 
macrophage can induce a T-cell response and change the phenotype of naïve T-cells to 
regulatory T-cells, Th17, Th1, or Th2 helper cells [37-39]. Changes in the ratios or balance of 
supportive and detrimental T-cells subtypes can be pathological [40, 41]. In addition, the other 
aspect of the adaptive immune response, antibody production, is also impaired by Meth. In 
mice, the levels and the type of Ig antibodies produced were hindered in mice that were given 
increasing doses of Meth [8]. Lastly, Meth hinders several roles of macrophage function 
particularly cytokine expression and thus, greatly prevents the macrophage’s ability to respond 
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Alterations in Expression of HDACs and Levels Post-
translational Modifications in HIV-1-infected, 





3.1.1. Discovery of HIV and subsequent pandemic 
 The first official documentation published by the US Centers for Disease Control 
and Prevention (CDC) on 5th June 1981 entitled “Pneumocystis Pneumonia – Los 
Angeles” outlined five cases of young gay men hospitalized with pneumonia, 
cytomegalovirus, and disseminated candida infections [1]. A month later, the New York 
Times reported that a total of 41 homosexual men had been diagnosed with Kaposi ’s 
sarcoma, a rare skin cancer [2]. This unknown disease was spreading rapidly and at the 
end of 1981, 5 to 6 new cases of the disease were being reported each week [3]. It was 
unclear how young and previously healthy individuals were succumbing to such deadly 
opportunistic infections but assumed the condition was limited to the gay population, 
hemophiliacs, intravenous drug users, and immunocompromised individuals. In July 
1982, at a meeting in Washington, D.C., the condition or disease was termed Acquired 
Immune Deficiency Syndrome (AIDS) [3, 4]. The CDC reported that the incidence of 
AIDS had risen from less than 6 per week to an average of one to two cases being 
diagnosed in the USA every day [5]. By the end of 1983 the number of AIDS diagnoses 
reported in the USA was 3,064 with an alarming 42.2% of them deceased [6]. In 1984, 
French scientists isolated the Human Immunodeficiency Virus (HIV) from the lymph 
node of infected patients that was the causative agent responsible for AIDS pandemic 
seen in earlier years [7]. 
HIV infection became a global pandemic with an estimated 35.3 million cases 
worldwide and 1.4 million people of those infected live in North America as of 2013 (Fig. 
3.1.) [8, 9] HIV has since its discovery been subcategorized into two types, HIV-1 and 
HIV-2. HIV-1 is the most common type of the virus, while HIV-2 is predominately in 
Western African [10]. 
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Figure 3.1. Number of People Living with HIV as of 2013 (Source: UNAIDS) 
 
3.1.2. HIV structure and life cycle 
HIV is a lentivirus of the retroviridae family. Lenti or lente translates to ‘slow’ in 
Latin and means HIV can be latent for a long period of time before it becomes active and 
pathogenic. The retroviridae family of viruses means the genetic material of HIV is RNA 
(in the case for HIV, two single stranded RNA molecules) as opposed to DNA. The viral 
genome consists of 9 genes (gag, pol, env, tat, rev, nef, vif, vpr, and vpu) and 15 distinct 
proteins [11]. There are six structural proteins: matrix (MA), capsid (CA), nucleocapsid 
(NC), p6, glycoprotein 120 (gp120) and gp41; three enzymes: protease (PR), reverse 
transcriptase (RT), and integrase (IN); two essential proteins: Tat, and Rev and four 
additional proteins called accessory proteins: Vif, Vpr, Vpu, and Nef, of which Rev and 
Tat are essential since they are compulsory for the transcription of daughter virus 
particles [12, 13]. The others are accessory as they are dispensible for replication in 
vitro, but required for pathogenesis in vivo.  
HIV is packaged into virons that contains all necessary components for the virus 
to travel throughout the bloodstream and infect other cells. The formation of virions can 
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be divided into three stages: assembly, in which the viral proteins are created and 
essential components are packaged; budding, wherein the virion crosses the plasma 
membrane and obtains its lipid envelope; and maturation, where the virion structure 
changes and becomes infectious [14]. An HIV virion is approximately 100 to 150 nm in 
diameter and is made up of a viral envelope and viral core. The viral envelope  
Figure 3.2. The Steps of the HIV Life Cycle. (Source: Adapted from Nature Reviews 
[15]) 
is a lipid bilayer derived from host’s plasma membrane during budding. A number of host 
cell proteins and viral specific glycoproteins are associated with the envelope. These 
viral glycoproteins, both encoded by the HIV env gene, are glycoprotein 120 (gp120), 
which is non-covalently linked to the transmembrane glycoprotein 41 (gp41). The core 
(or capsid) of the virion consists of a cone-shaped protein p24 and protects the viral 
genome and the three enzymes RT, PR, and IN that are essential for the survival and 
infectivity of HIV [16]. 
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The HIV life cycle starts with HIV gp120 on the surface of the virion attaching to 
the CD4 co-receptor on the host cell. A conformational change in gp120 allows further 
interaction with either, CXCR4 (X4) or CCR5 (R5) co-receptors [17]. Once gp120 
interacts with both CD4 and either chemokine receptor it results in the insertion of the 
fusion peptide into the host cell membrane to initiate fusion of the viral and host cell 
membranes. The viral core is then released in to the cytoplasm of the host [18]. Next, 
the viral RNA is reversed transcribed by the prepackaged viral enzyme RT. The cDNA of 
HIV translocates to the nucleus using a number of host’s proteins as chaperones and is 
integrated into the host DNA using IN [19, 20]. When activated, the proviral DNA is 
transcribed and translated. Two of the first viral proteins to be translated to positively 
regulate transcription are Tat (trans-activator of transcriptional) and Rev (regulator of 
expression of virion proteins). The large polypeptide chains comprising of viral core 
envelope (Env) and gag proteins are cleaved in to smaller fractions. HIV RNA, the viral 
Env protein, the Gag polyprotein, and the three viral enzymes: PR, RT, and IN assemble 
near the host’s plasma membrane and results in budding of a new infectious particle [15] 
(Fig. 3.2.). 
3.1.3. Common therapy for HIV-1 infection 
The treatment strategies for HIV positive individuals are designed to primarily 
target viral enzymes as well as virus entry to prevent the progression of the various 
stages of the viral life cycle. The FDA approved drugs for HIV fall in to 6 different 
classes: non-nucleoside reverse transcriptase inhibitors (NNRTI) nucleoside reverse 
transcriptase inhibitors (NRTI), protease inhibitors (PI), fusion inhibitors, entry inhibitors 
(also called chemokine receptor antagonists), and integrase strand transfer inhibitors 
(INSTI). NRTI were the first class of drug to be approved by the FDA and inhibits RT 
with modifed nucleosides that bind to viral DNA and halt the elongation by RT. Tenofovir 
(TDF), trade name Viread, is an FDA approved NRTI and although being synthesized in 
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1984, it was not approved until 2001. However, TDF is on the World Health 
Organization's (WHO) List of Essential Medicines for preventing and treating HIV and 
chronic Hepatitis B, a common co-infection [21-23]. Another common and NRTI is 
Emtricitabine (FTC) and is available as a monotherapy or as a fixed dose together with 
TDF, trade names Emtriva and Truvada, respectively [24]. During the mid-90s, the PI 
class of drug was introduced. As the name indicates, PI prevents viral replication by 
selectively binding to PR, which is critical for the cleavage of protein precursors into the 
mature infectious proteins therefore, no active enzymes or budding can occur. 
Atazanavir (ATV), trade name Reyataz®, was the first approved PI for once daily dosing 
and is also on the WHO List of Essential Medicines. 
Due to HIV mutating and development of drug resistance, the standard regimen 
of treating HIV is with combinational antiretroviral therapies (cART) using drugs from 
different classes, two NRTI/NNRTI and one PI/INSTI [25, 26]. The newer classes of 
drugs that are also useful in cases when drug resistance occurs against PI and RT 
inhibitors are entry inhibitors and INSTI [27]. The entry inhibitors in particular target the 
different stages of HIV entry, binding to either the CD4 or CCR5 receptors, or fusion of 
gp41, onto CD4+ cells. Maraviroc and Enfuviritide are currently approved members in 
this group. Following the success of triple combination therapy, morbidity and mortality 
decreased drastically, making what was once a death sentence into a chronic condition 
where the life expectancy is now almost equal to healthy averages (~70%) [28, 29]. 
3.1.4. Meth use and HIV risk  
 HIV-1 infection and Meth addiction are serious and common comorbidities [30, 
31]. Prevalence of both comorbidities is hard to determine since the prevalence is reliant 
on the region, the person’s sexual orientation, whether or not the use of Meth is chronic 
or sporadic, and whether or not Meth is injected [32, 33]. Regardless of why HIV positive 
patients abuse Meth, it is often accompanied with unsafe sex practices as the effects of 
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Meth result in increases in sexual libido while decreasing judgment and inhibition, 
thereby increasing risk for HIV transmission [34]. Another issue with concurrent Meth 
use and positive HIV status is a decrease in adherence to HIV treatment and medical 
visits [35]. Frequent Meth use has also been associated with increased risk for 
antiretroviral resistance, particularly to NNRTIs and possible fatal interactions when used 
with PI [36-38]. All the risk factors taken together is shocking as Meth use can increase 
the risk for new HIV transmission cases through sexual activity and also contribute to 
poorer health outcomes in HIV-infected individuals. 
Meth can be smoked, ingested (orally or anally), or injected, though the latter 
holds an increased risk in the case of sharing needles to spread HIV and other blood 
borne viruses [21, 39]. An estimated 20-40% of injecting drug users are HIV positive 
equating to about 3·0 million (range 0·8–6·6 million) people worldwide [33]. Although the 
percentage of injecting drug users includes other types of illicit drugs besides Meth, the 
astounding number is a major issue and risk to global public health. 
3.1.5. HIV-1 latency and role of epigenetics 
 Epigenetics is the study of cellular factors and the mechanisms that help control 
gene expression that are not caused by the changes in DNA sequence. Research shows 
that epigenetics is, at least partially, contributes to inheriting addictive behaviors, aging, 
neuronal plasticity, and memory formation [40-43]. Post-translational modifications 
(PTM) to the histone N-terminal (“histone tails”) and DNA methylation are the two 
epigenetic mechanisms that regulate gene expression. The number and type of PTM 
(acetylation, methylation, phosphorylation, and mono- di-, or tri-) as well as location 
(which residue), and combination can indicate gene transcription or repression. This is 
referred to as the histone code [44, 45]. For example, methylation of histones can occur 
on lysine or arginine residues and can be mono- (Me), di- (Me2), or trimethylated (Me3). 
Acetylation (Ac) occurs on lysines but due to the neutralization of ε-amino group, only 
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one acetyl moiety can occur per lysine. Phosphorylation (P) occurs on serine and 
threonine residues and similar to acetylation can occur only once but for a different 
reason, the presence of one hydroxyl group. Ubiquitination (Ub) can occur on lysines 
and is complex because there can be one (mono-) or long chains of Ub 
(polyubiquitinated). Given the number of different types of PTM and number of amino 
acids they may or may not occur on and considering them occurring on multiple residues 
simultaneously, the number of possibilities to decipher the histone code is extensive. 
However, using a reductionist approach, the fundamentals have begun to be 
determined, including how a single PTM alters transcription, or if enzymes demonstrate 
specificity to which histone substrate [46-48]. For example, acetylation of lysine 
residues, although not always, will activate transcription whereas, a non-modified lysine 
inhibits transcription as well as DNA methylation [49, 50]. 
Of particular interest are the epigenetic mechanisms regulating HIV expression. 
The most studied PTM and mechanism in regards to HIV transcription is acetylation and 
deacetylation. The enzymes that accomplish the addition and removal of acetyl groups 
are called histone acetyltransferases (HAT) and histone deacetylases (HDAC), 
respectively. HDACs are classified as Class I or Class II. HDACs are divided and 
grouped together based on the sequence homology to the yeast counterparts however, 
a big difference between the localization of the two classes. Class I HDACs (HDAC1, 2, 
3, and 8) are primarily found in the nucleus whereas, Class II HDACs (HDAC4, 5, 7, and 
9) shuttle between the cytosol and nucleus. One HDAC in particular, HDAC1, was found 
to silence HIV expression but when incorporated into virions help facilitated entry of HIV 
into other cells [51, 52]. Even though cART has been able to control the virus to below 
detection levels, latent HIV exists in long-lived memory CD4+ T-cells and macrophages 
and prevents complete eradication of infection [53, 54]. Therefore, studies have used 
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HDAC inhibitors (HDACi) to open the chromatin and reactivate the expression of viral 
genes so that new therapies can target latently infected cells [55-57]. 
Epigenetic mechanisms are not only of interest to the field of HIV research but as 
mentioned previously, studied in the cases of drug addiction by itself or with both 
comorbidities (HIV and addiction) [40, 58]. Changes in gene transcription in the midbrain 
seen after chronic Meth exposure have been correlated with increases in the histone 
PTM acetylation as well as a decrease in HDAC1 protein [59-62]. There is evidence that 
epigenetic mechanisms regulate the viral genome and how that is altered in Meth 
abusers still needs to be determined so that reservoirs can be depleted and HIV finally 
eradiated. Therefore, the goal of our study is to identify the key factors involved in 
affecting HIV transcription using macrophages as a model of the immune function 
dysregulation in Meth abusers on cART.  
 
3.2. Materials and Methods 
3.2.1. Cell culture and sample preparation 
Primary human monocytes were obtained through leukophoresis from donors 
who were seronegative for HIV-1, HIV-2, and hepatitis B virus. These monocytes were 
purified using counter-current centrifugal elutriation and cultured at a final concentration 
of 1 million per mL in macrophage serum-free medium (MSFM) (Invitrogen; Carlsbad, 
CA)[63]. MSFM was supplemented with a 1% HEPES buffer (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid)) (Invitrogen); 1% Nutridoma (Roche Diagnostics GmbH; 
Indianapolis, IN), and 10 ng/mL Macrophage-colony stimulating factor (MCSF) 
(PeproTech; Rocky Hill, NJ). Half of the media volume was exchanged every other day. 
After seven days of differentiation monocytes are considered monocyte-derived 
macrophages (MDM) and no longer require MCSF and therefore, HIV-1ADA infection was 
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diluted in new MSFM at a multiplicity of infection of one (MOI:1) for 4 h at 37°C. After, 
virus media is removed and replaced with fresh MSFM with the above defined 
supplements. On day 10, Meth (Sigma-Aldrich; St. Louis, MO) added at a concentration 
of 100 µM. Two days later on day 12, full media was removed and ATV, TDF, and FTC 
(henceforth referred to as cART) was added to fresh media, each at an efficacious 
concentration of 5 µM. All media was removed and cells were washed three times with 
phosphate buffered saline (PBS; HyClone; Logan, UT) before conditions were harvested 
on day 17 (Fig. 3.3.). Macrophages were lysed for RNA, whole cell lysates (WCL), or 
fractionated into subcellular parts using the Qproteome Nuclear Protein Kit (Qiagen; 
Germantown, MD) according to manufacturer’s protocol (Fig. 3.4.). To obtain protein 
from WCL, cells were scraped in PBS and pelleted by centrifugation at 1000 x g for 5 
min at 4°C and re-suspended in 300 µL per 106 cells of lysis buffer. Lysis buffer 
contained 4% (w/v) SDS (Bio-Rad; Hercules, CA), in 0.1 M Tris-HCl (Fisher Scientific; 
Fair Lawn, NJ), 0.1 M DTT (Promega; Madison, WI) and 1X Protease Inhibitor Cocktail 
(Sigma-Aldrich). Cells were boiled at 95°C for 5 min, allowed to cool, and 100 units/mL 
Benzonase Nuclease (Merck KGaA; Darmstadt, Germany) was added. All protein 
samples were quantified using Pierce 660 Assay as per the manufacturer’s protocol 
using 50 mM ionic detergent compatible reagent (Thermo Scientific; Rockford, IL). 
3.2.2. Quantification of HDAC levels and histone PTMs by Western blot 
Five micrograms of cytosolic, nuclear, or WCL proteins were loaded onto Tris-
Glycine gels (Invitrogen) and separated using one-dimensional electrophoresis. Proteins 
were immediately transferred to a PVDF membrane (Bio-Rad; Hercules, CA) and 
blocked overnight at 4°C in 5% milk in Tris-Buffered Saline supplemented with 0.2% 
Tween 20 (TBST) (both from Fisher Scientific). Nuclear fraction was used to blot for 
HDAC antibodies that were from a commercial source: HDAC1-6 (1:1000) for 1 h and 
horseradish peroxidase (HRP) secondary (1:1000) at room temperature for 1 h (Cell 
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Signaling Technologies; Beverly, MA). Washes were performed after primary and 
secondary antibodies using TBST three times for 5 min each. Three PTMs were studied, 
acetylation on lysine 5 histone 4 (H4K5ac), acetylation on lysine 9 histone 3 (H3K9ac), 
and acetylation on lysine 18 histone 3 (H3K18ac) (all from Abcam; Cambridge, UK) all at 
1:1000. Each of the three PTM primary antibodies were incubated at 4°C overnight. 
Three washes for 5 min each were performed with TBST before and after adding HRP 
secondary antibody (Jackson ImmunoResearch; West Grove, PA) at 1:20000 at room 
temperature for 30 min. Each blot was incubated at a 1:1 ratio with TMA-6 Solution A 
and B enhanced chemiluminescence (Lumingen; Southfield, MI) in the dark for 1 min 
and exposed for 3 seconds. The density of the band was calculated on the Kodak 
CareStream Imaging System Image. Three biological replicates/donors were used for 
quantifying HDACs. Student’s t-test was performed on the intensity valued after 
normalization to the intensity of actin.  
3.2.3. RNA extraction and relative quantitative PCR 
Cells were lysed directly in the culture dish with Trizol Reagent (Life 
Technologies; Carlsbad, CA). RNA was resuspended in 10 mM Tris (Pro-Pure, Solon, 
OH) and 1 mM EDTA (Fisher Scientific), pH 8.0 in RNase free water. One microgram of 
RNA was converted to cDNA using the High Capacity cDNA Reverse Transcription Kit 
(Life Technologies) per the manufacturer’s protocol. The primers used were human 
HDAC1 and HDAC6 (both Integrated DNA Technologies; Coralville, IA) and human 
GAPDH primers were used for normalization (Applied Biosystems; Warrington, UK). The 
relative abundance of each gene was calculated using the comparative CT method [64] 
3.2.4. Imaging of HDAC1 colocalization by confocal microscopy  
Primary human MDM were cultured in 8-well chamber slides at a density of 
500,000 cells per well. Cells were exposed to either MSFM for control or 100 µM Meth 
for 24 h at 37°C. Wells were washed 3 times with Tris-buffered saline (TBS, Sigma-
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Aldrich), fixed with 4% paraformaldehyde (PFA, Sigma-Aldrich) for 30 min, 
permeabilized and blocked simultaneously with 0.1% Triton (Thermo Fisher; Waltham, 
MA) and 10% normal goat serum (NGS, Vector Laboratories; Burlingame, CA) in TBS 
and then quenched with 50 mM NH4Cl (Sigma-Aldrich) for 15 min. The cells were 
washed with 0.5% Tween (Thermo Fisher) in TBS (TTBS) and incubated at (1:100) for 
the primary antibodies rhodamine-conjugated phalloidin (Life Technologies) and 1 µg/mL 
of HDAC1 (Abcam) in 10% NGS for 1 h at 37°C. The cells were then washed with TTBS 
and incubated with the secondary antibody conjugated to Alexa Fluor 488 for 45 min at 
37°C. One μg/mL of DAPI (Invitrogen) for 5 min was used to stain nuclei and after one 
wash with water and one wash with TBS, one drop of Prolong Gold (Invitrogen) was 
added before the slides were cover slipped. Images were captured using the Zeiss Meta 
510 confocal microscope (Carl Zeiss, Inc., Thornwood, NY, USA) and Zen lite Imaging 




3.3.1. Quantification of HDACs 
 Given the ambiguity for the roles of HDACs in HIV or Meth use in macrophages, 
we measured the protein levels of some HDACs from Class I and Class II in an unbiased 
manner in all 8 conditions (Fig. 3.4). Cells were fractionated into nuclear and cytoplasmic 
proteins to decipher the localization of each. HDAC1-4 were detected in both the cytosol 
(Fig. 3.6.) and the nucleus (Fig. 3.7.). Surprisingly, HDAC5 and 6 were never detected in 
any of the three donors. The only HDAC with a statistical difference in expression 
compared to control cells was HDAC1 in Meth treated MDM, although there was also a 
trend for decreased HDAC1 in the nucleus (Fig. 3.8.). To confirm the localization of 
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HDAC1 protein, we used confocal microscopy to visualize and quantify HDAC1 in Meth 
exposed MDM. In the previous quantitative Western blot experiments MDM were 
exposed for 48 h, the confocal images were taken after only 24 h of exposure. Even so, 
HDAC1 was found to be decreased significantly compared to control (or mock treated 
macrophages) (Fig. 3.9.). Next, we sougt to determine the mechanism of decreased 
HDAC1 protein either decreased transcription, altered PTMs, increased degradation, or 
both altered PTMs and degradation [66]. To do this we first isolated the total RNA and 
performed RT-qPCR on HDAC1 and HDAC6. We observed that HDAC1 was highly 
expressed in control cells (data not shown) but drastically decreased in Meth treated 
MDM. In contrast, HDAC6 levels barely increased compared to control cells (Table. 
3.1.). In order to overcome the donor to donor variability in the Western blots from all 8 
conditions, separate cell cultures were conducted with fewer treatments and instead of 
fractionation we performed a WCL to extract all the proteins and reblotted for HDAC1. 
Much to our surprise, HDAC1 was no longer decreased in Meth treated MDM compared 
to control (Fig. 3.10.). In fact, no treatments reached significance for HDAC1 in WCL.  
3.3.2. Consequences of decreased HDAC1 is changes in the histone acetylation  
Decreases in HDAC1 would be expected to lead to increases in HDAC1-specific 
acetylation sites. Some PTMs that have been reported to be specific to HDAC1 by ChIP 
are histone 4 lysine 5 (H3K5), histone 3 lysine 18 (H3K18), and histone 3 lysine 9 
(H3K9) [67, 68]. As expected with decreased HDAC1, we observed a large increase of 












Table 3.1. Expression levels of HDAC1 and HDAC6. MDM were cultured with 100 µM 
Meth or control (MSFM) for 48 hours. Total mRNA was extracted and PCR was 
performed. Relative to control Meth caused a significant decrease of HDAC1 mRNA but 
not HDAC6. Data are represented as the mean±SD fold expression of 3 independent 
experiments. An asterisk (*) indicates p<0.05 by a Student’s t-test whereas, ‘ns’ is not 
statistically significant. Fold changes are normalized to the housekeeping gene GAPDH. 
  
Gene HDAC1 HDAC6 









Figure 3.3. Timeline for treatments. Monocytes are differentiated in the presence of 
MCSF for 7 days. On day 7, MDM are infected with HIV-1ADA. Three days post-infection, 
MDM are exposed to 100 µM Meth and maintained for 48 h. On day 12 days post-plating 
or 5 days post-infection MDM are treated with cART (ATV, FTC, and TDF) at 5 µM each 






Figure 3.4. Schematic of sample preparation. A diagram of how the macrophages will 













Figure 3.5. Experimental conditions for elucidating the effects of HIV infection, 
Meth abuse, and antiretroviral therapy on the transcriptional machinery in 
macrophages. Macrophages will be infected, exposed to Meth and/or treated with cART 
constituting a total of 8 experimental conditions to determine the individual and 






Figure 3.6. Protein levels of HDACs in the cytosol. Description of treatments and 
timeline refer to Figure 3.3. Proteins extracted from the cytosol of MDM and levels of 
HDAC1-6 were quantified Densities of HDAC1 were normalized to actin using ImageJ 







Figure 3.7. Quantification of HDAC protein levels in the nuclear fraction. 
Description of treatments and timeline refer to Figure 3.3. Densities of HDAC1 were 
normalized to actin using ImageJ software. Data are represented as the mean±SE fold 






Figure 3.8. Protein levels of HDAC1 from the cytosol and nucleus in control and 
Meth treated human macrophages. Plot re-represents the samples juxtaposed for 
HDAC1 from the levels in the cytosol and nucleus (Fig. 3.5. & 3.6). MDM were either 
mock treated (control media) or with 100 µM Meth for 48 h and then maintained for 5 
days with no other treatments. MDM were fractionated and HDAC1 protein was detected 
by Western blot. An asterisk (*) indicates p<0.05 by a Student’s t-test. Densities of 







Figure 3.9. Confocal images of MDM stained for HDAC1. MDM were cultured on 
glass chamber slides with 100 µM Meth or control (MSFM) for 24 h. HDAC1 antibody 
(green), actin (red), and Dapi (blue). Merged images show the co-localization of HDAC1 
with actin (yellow). Row (a) Control MDM. Row (b) Meth exposed MDM. Bar graph is the 































































































ImageJ software. Single image capture at 63X oil immersion objective. An asterisk (*) 






Figure 3.10. HDAC1 levels in WCL. In a separate experiment, MDM were either mock 
treated (control media), exposed to 100 µM Meth, or infected with HIV-1. Keeping with a 
similar timeline when there was 8 conditions, MDM were infected on day 7 and exposed 
to Meth on day 10, then maintained for 48 hours before being lysed and proteins 
extracted. Quantitative Western blot analysis of HDAC1 from 5 µg of each sample. of 






Figure 3.11.  Western blot analysis of acetylation of H4K5 and H3K18. Two known 
targets for HDAC1 are H4K5 and H3K18 and changes in HDAC1 will effect acetylation at 
these sites. Control and Meth MDM treatment was described in Cell Culture and Sample 
Preparation (section 4.2.1). Five µg of histones from each sample were loaded and 





 In this study, we found that Meth decreases HDAC1 at the protein level. This was 
explained by the corresponding decrease in mRNA levels. A decrease in HDAC2-6 
protein levels or a decrease in HDAC6 mRNA would have been an indicator that Meth 
exacerbates the degradation pathway or inhibits translation, respectively. Our conclusion 
from not detecting HDAC5 and 6 by Western blot is that the antibodies were not specific 
enough considering HDAC6 was quantified using the more sensitive technique, RT-
qPCR. In addition, the low number of cell cultures or high variability of HDAC levels 
among healthy donors might have contributed to HDAC2-4 being inconclusive. 
Therefore, more studies need to be done with more donors to verify that Meth, HIV-1 
infection, and/or cART do not have an effect on HDAC2-6 levels. The confocal images, 
relative quantification of HDAC1 by RT-PCR and the correlation between the increases 
in acetylation and HDAC1, allowed us to conclude that Meth induces a decrease in both 
the protein and RNA level. This is analogous to other reports on Meth addict brains 
suggesting a similar mechanism in macrophages [61, 62].  
The rationale that HDACs result in gene silencing is twofold: one, because of the 
biochemistry between the histone tails and DNA and two, because of in vitro data. Non-
acetylated (or deacetylated by HDACs) lysine residues on the N-terminal histone tails 
are positively charged and electrostatically attracted to the negatively charged 
phosphate backbone of DNA. This interaction between DNA and histones tails keep 
chromatin in a closed formation and inaccessible for transcription. Another reason HDAC 
is associated with gene repression is treatment with HDACi resulted in the abrogation of 
gene repression [69, 70]. However more recently, it has been found that HDAC1 is 
present at many transcriptionally active genes [71]. Therefore, whether the downstream 
effect of the Meth-induced decrease of HDAC1 is gene silencing or activating still needs 
to be explored. 
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The rapid decreases of HDAC1 within 24 h of Meth exposure was expected 
because Meth increases cytokine production and HDAC1 suppresses the NF-κB-
dependent genes like TNF-α, IFN-β and other cytokines in macrophages and T-cells [72-
77]. However, it was surprising to see no changes in HDAC1 in the HIV or HIV/Meth 
samples and especially, HIV/Meth not having an additive effect on HDAC1. Literature 
would suggest that HIV dysregulates HDAC1 to allow for the expression of viral genes 
and our macrophages are actively producing HIV (p24 ELISA not shown). One 
explanation is, again, that the number of cell cultures was not robust enough to 
demonstrate statistical significance as there is a trend of decreased HDAC1 in the 
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Method Development: Pressure Assisted Digestion of 





 Sample preparation for high-throughput analyses of proteins is at the center of 
proteomic profiling experiments [1-4]. The multi-step nature of proteomic studies makes 
reproducibility, standardization, and normalization key to reducing analytical variability. 
Other than intact protein analysis and the rarely used chemical methods for protein 
digestion, the majority of proteomic experiments contain a step involving the enzymatic 
digestion of proteins for mass spectrometry (MS)1-based protein identification and 
quantitation. It is important to note that each type of proteolytic digestion can yield a 
different number and type of peptides, thereby limiting the scope of information related to 
the structure and function of the protein of interest [4]. Therefore, the concept of a 
universal sample preparation method has several limitations, thereby driving 
technological and methodological development to create new avenues for enhancing 
sample preparation.  
Conventional enzymatic digestion protocols typically employ an overnight 
reaction to ensure complete digestion of peptides. Still, samples can contain cleavage 
sites that are missed during digestion. Namely, a reduced rate of specific peptide bond 
hydrolysis and/or the presence of posttranslational modifications (PTMs) contribute to 
this effect [5]. Several techniques, such as high-intensity focused ultrasound (HIFU), 
microwave radiation, and performing the digestion under conditions of high pressure, 
have been developed and modified to overcome these digestion shortcomings and to 
decrease the time needed for complete digestion of the protein [6-11]. The technique 
involving high-pressure conditions applies pressure up to 40 kpsi and appears to provide 
improved results as compared with HIFU and microwave radiation. HIFU is based on 
precise modulation of ultrasound, which was a significant problem in the past; however, 
current ultrasound techniques have found application (e.g., electrical impedance 
tomography, optical tomography) [12]. On the other hand, reactions controlled by 
104 
 
microwave radiation are so rapid that the generated reaction heat can lead to by-product 
formation and, in some cases, to degradation. The limitations of HIFU and microwave 
radiation have prompted us to test whether pressure cycling technology (PCT) can be 
used sufficiently for accelerated enzymatic digestion and be applicable in proteomics. 
The use of PCT for enhancing enzyme activity was introduced during the early 
1990s. However, the development of new instrumentation resulted in more user-friendly 
methods, leading to development of new applications [13, 14]. Here, we evaluate the 
Barocycler NEP 2320 (Pressure Biosciences, South Easton, MA, USA) as a platform for 
analyzing the enzymatic digestion of proteins under high pressure. The Barocycler NEP 
2320 applies PCT to accelerate enzymatic digestion of samples, which in turn are used 
for analytical purposes. In the current study, histone H4 is used as the model protein. 
Histones, in addition to their functions in epigenetic regulation, represent a class of 
proteins that can carry multiple homo and heterogeneous PTMs, thereby altering 
susceptibility for enzymatic digestion, which subsequently causes additional difficulties in 
profiling studies. Using PCT, we were able to reduce the time of enzymatic digestion of 
histone H4 from 18 h to 120 min while maintaining 100% of sequence coverage 
identified by tandem MS (MS/MS) after digestion under atmospheric pressure. 
 
4.2. Materials and Methods 
4.2.1. Reagents 
High-performance liquid chromatography (HPLC) gradient-grade acetonitrile 
(ACN) and water were purchased from Fisher Scientific (Fair Lawn, NJ, USA). 
Trifluoroacetic acid (TFA, Reagent-Plus, 99%), urea, ammonium bicarbonate 
(ReagentPlus, 99%), iodoacetamide (IAA, Sigma Ultra), and α-cyano-4-hydroxycinnamic 
acid (CHCA) were purchased from Sigma–Aldrich (St. Louis, MO, USA). Molecular-
105 
 
grade dithiothreitol (DTT) and sequencing-grade chymotrypsin were purchased from 
Promega (Madison, WI, USA). Recombinant human histone H4 (P62805) was 
purchased from New England Biolabs (Ipswich, MA, USA). Primary human monocytes, 
obtained by elutriation from healthy donors, were used to isolate histone fractions using 
a Qproteome Nuclear Protein Kit (Qiagen, Hilden, Germany) [15, 16]. The protein 
fractions obtained using Qproteome were quantitated using a Pierce 660-nm protein 
assay and prediluted protein standards (bovine serum albumin, Thermo Scientific, 
Rockford, IL, USA). 
4.2.2. Histone fractionation 
The histones were isolated from the primary human monocytes using the Qproteome kit 
from Qiagen. The isolated histones were further fractionated using a reversed phase 
HPLC (RP–HPLC) system (Shimadzu Scientific Instruments, Columbia, MD, USA), 
which was equipped with an ultraviolet (UV) detector and Shimadzu LC Solution 
software for data acquisition. Chromatographic separations of 100 μg of proteins per 
injection were performed using an analytical HPLC C4 column (250 × 4.6 mm, dp = 5 
μm, 300 Å) from Advanced Chromatography Technologies (Aberdeen, Scotland). Mobile 
phase A was 5% ACN in water plus 0.1% TFA, and mobile phase B was 90% ACN plus 
0.1% TFA. Fractionation was initiated with 100% mobile phase A for 5 min. From 5 to 15 
min, mobile phase B was ramped up to 35% and then held continuously for 10 min. 
From 25 to 100 min, the amount of solvent B was increased to 65%, followed by ramping 
up to 100% in 20 min. This condition was maintained for 5 min, and then the amount of 
solvent B was decreased to 0% in 5 min and held for 145 min.  
4.2.3. Enzymatic protein digestion 
Proteolytic digestion under atmospheric conditions was performed for at least 18 
h but no longer than 24 h. In this article, enzymatic digestion under atmospheric 
pressure is referred to as the “conventional method.” In this study, we compared 
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digestion assays of recombinant and native human histone H4 using the conventional 
method compared with PCT using a Barocycler NEP 2320. After completing digestions 
of recombinant protein, an AB SCIEX 4800 matrix-assisted laser desorption/ionization–
tandem time-of-flight (MALDI–TOF/TOF) mass spectrometer (Framingham, MA, USA) 
was used to analyze resulting peptides. A nano liquid chromatography (nanoLC) LTQ-
Orbitrap mass spectrometer was used to analyze peptides from digestions of native 
histone H4 isolated from human monocytes. 
4.2.4. Conventional method of proteolytic digestion 
Dried human histone H4 was dissolved in 20 μl of 8 M urea and 0.4 M NH4HCO3, 
and the pH was adjusted to between 7.5 and 8.5. Proteins were reduced by the addition 
of 5 μl of 45 mM DTT and incubated for 15 min at 50 °C. After cooling to room 
temperature, the sample was alkylated through the addition of 5 μl of 100 mMIAA and 
incubated in the dark at room temperature for 15 min. Following alkylation, the digestion 
buffer was diluted with water to a final concentration of 2 M urea and 0.1 M NH4HCO3. 
Chymotrypsin was added to the sample in a ratio of 1:4 (w/w) enzyme to protein. 
Digestion occurred at 37 °C for 18 h. Next, the reaction was quenched by acidifying the 
sample through the addition of 50 μl of TFA. 
4.2.5. PCT digestion 
All steps of the tryptic digestion protocol preceding incubation (ambient or high 
pressure) were identical for the Barocycler NEP 2320 and conventional methods. 
However, after the sample was alkylated, in the case of using the Barocycler NEP 2320, 
samples were transferred to PCT MicroTubes and placed in the metal holder component 




4.2.6. Mass spectrometry 
MALDI–TOF/TOF—In preparation for MS analysis, peptides resulting from PCT 
digestion of recombinant human histone H4 (1 μg) were desalted using reversed phase 
ZipTip pipette tips with 0.2 μl of C18 resin (Millipore, Billerica, MA, USA). For sample 
analysis, an AB SCIEX 4800 MALDI–TOF/TOF mass spectrometer was used. First, 1 μl 
of digested sample was spotted onto a MALDI plate and co-crystallized with 1 μl of 
CHCA matrix (5 mg/ml in 50% ACN and 0.1% TFA). The droplets were dried in a 
desiccator under decreased pressure. Spectra acquisition and data processing were 
performed using 4000 series Explorer software version 3.5.1 (AB SCIEX); the software 
settings were in a reflectron-positive mode at fixed laser intensity with a low-mass gate 
and delayed extraction. Peptide masses were acquired for m/z values ranging from 800 
to 2500 Da. MS spectra were summed from 1000 laser shots by an Nd-YAG laser 
operating at 355 nm and 200 Hz. MS/MS spectra were acquired in 1 kV positive mode. 
The 1000 shots were summed in increments of 50. Database searches were performed 
on the SwissProt database using Mascot MS/MS Ion Search 
(http://www.matrixscience.com). The search parameters were as follows: (i) 
carbamidomethylation on cysteine and oxidation on methionine were variable 
modifications; three missed chymotrypsin cleavage sites were permitted; the mass 
accuracy tolerance for the peptide (MS) was set at 15 ppm and for fragments (MS/MS) 
was set at 0.5 Da. 
ESI–LC–MS/MS—Histone H4 isolated and fractionated from human monocytes 
was digested using both conventional and PCT methods. After digestion, and prior to 
analysis, samples were desalted using reversed phase ZipTip pipette tips with 0.2 μl of 
C18 resin as per the manufacturer’s protocol (Millipore). Next, samples were analyzed 
using a high resolution mass spectrometry electrospray ionization (ESI)–LC–MS/MS 
system in a nanospray configuration (LTQOrbitrap, Thermo Scientific, West Palm Beach, 
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FL, USA) coupled with a nanoLC system (TEMPO nano MDLC System, AB SCIEX) and 
using a microcapillary RP-C18 column (New Objectives, Wo-burn, MA, USA). The 
database search was performed using Proteome Discoverer 1.2 software (Thermo 
Scientific). The search parameters were as follows: (i) carbamidomethylation on cysteine 
and oxidation on methionine were variable modifications; three missed chymotrypsin 
cleavage sites were permitted; the mass accuracy tolerance for the peptide (MS) was 
set at 15 ppm and for fragments (MS/MS) was set at 0.5 Da. 
 
4.3. Results 
4.3.1. Pressure optimization 
To optimize the pressure and time for the digestion for recombinant human 
histone H4, we performed multiple digestions at different pressures and for different time 
points (see Tables 4.1 and 4.2 below). Experiments were performed in triplicate. Based 
on manufacturer recommendations, we selected the following three pressure settings: 
10, 15, and 25 kpsi. Cycling consisted of 30 cycles at 1 min each; each cycle was run for 
50 s at the pressure setting of interest, followed by 10 s of stabilization at atmospheric 
pressure. The temperature was ambient, and chymotrypsin was used at a concentration 
of 0.5 μg/μl. The resulting digest of the protein was analyzed using an AB SCIEX 4800 
MALDI–TOF/TOF mass spectrometer for the recombinant histone H4. The digest of 
recombinant histone H4 revealed seven peptides and constituted a nearly full sequence 
except for the first amino acid and the C-terminal fragment, a 100GFGG103 (MW = 
336.14) tetrapeptide. The peak list, created by 4000 series Explorer software, was used 
in parallel to acquire MALDI–TOF/TOF data. This data consisted of (i) the m/z ratio 
(including an average mass with lower and higher m/z recordings), the peak height 
(peak intensity), the signal/noise ratio, (iv) resolution, and (v) the area under the peak. 
The peak with highest intensity represents 100%. Considering that in each experiment 
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the only variable parameter is the applied pressure, we theorized that peak intensity 
would reflect the relative change in the amounts of each peptide generated by such 
digestion, thereby more of any given peptide in the mixture. The m/z peak of such a 
peptide is expected to have higher intensity. Therefore, we elected to demonstrate 
pressure optimization based on the relative comparison of peak intensities for each 
peptide generated using pressures of 10, 15, and 25 kpsi. Results for all peptides are 
summarized in Table 4.1, and Fig. 4.1 is a bar graph comparing the changes in peak 
intensity for the two N-terminally located peptides that are postulated to be of the 
greatest biological importance. In all three samples (10, 15, and 25 kpsi), the peptide 
90ALKRQGRTLY99 showed the highest intensity, thereby setting up 100%, which were 
0.24 1.2, and 1.3 × 104, respectively. Based on these data, we postulated that we did 
not reach the signal saturation for this mixture of peptides under our experimental 
conditions, thereby allowing us to make relative comparisons. Comparisons should be 
performed with caution and can be performed for only a single peptide at three digestion 
conditions (horizontally, e.g., for one given peptide), assuming that the rate of ionization 
remains constant and signal suppression from other peptides is negligible. Based on the 
data presented, it was determined that a pressure of 10 kpsi was too low, as reflected by 
the low signal intensity overall and for each of the seven peptides. When comparing 
peak intensities for pressures of 15 and 25 kpsi, results indicate that 15 kpsi was 
beneficial for the signal intensity of peptides 1, 2, and 5 (see Table 4.1), which were 
further digested and/or degraded at 25 kpsi. If low-specificity chymotrypsin was used, we 
would expect that the peptide 74TEHAKRKTVTAMDVVY89 would be further fragmented 
into the following three peptides: 74TEH76, 77AKRKTV-TAM85, and 86DVVY89. This 
fragmentation is expected to result in a drop in the peak intensity for this particular intact 
peptide. For example, when low-specificity chymotrypsin is used, the peptide 
2SGRGKGGKGLGKGGAKRHRKVL23 could be further fragmented at 25 kpsi into the 
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following three peptides: 2SGRGKGGKGL11, 12GKGGAKR18, and 19HRKVL23. 
Because this was not observed, we conclude that susceptibility of peptide bonds cleaved 
under PCT conditions is, to some extent, selective. This selective cleavage could be 
advantageous if one investigates proteins with point mutations, splice variants, and/or 
isoforms and when the aim of the experiment is not only to have maximal sequence 
coverage but also to have overlapping sequences. For other peptides, a pressure of 25 
kpsi appears to be optimal. It has been postulated that, from a biological point of view, 
the most important part for all histones is the N-terminus end (also called the “histone 
tail”) [17]. This end is arbitrarily set to be approximately 30% of sequence from the N-
terminal end of histones; in histone H4, this would be the first 38 amino acids [18]. The 
N-terminus portion of histone has been shown to play an important role in chromatin 
remodeling and transcription regulation. In summary, we conclude that 15 kpsi is the 
optimal pressure to digest histones for further studies. 
4.3.2. Time optimization at 15 kpsi 
Based on reasoning presented above with respect to fragmentation and pressure, we 
attempted to optimize digestion time at a pressure of 15 kpsi. For this part of data 
analysis and interpretation, we used the same criteria as we used for analysis applied to 
pressure optimization as described in the previous section. Results for all peptides are 
presented in Table 4.2, and Fig. 4.2 is a bar graph comparing the changes in peak 
intensity for the two N-terminally located peptides that are postulated to be of the 
greatest biological importance. For peptides 1, 2, 3, and 5, the optimal time appears to 
be 120 min; when extended, this leads to a decrease in the signal intensity. The 
decrease in the peak intensity for the peptides shown in Table 4.2 would again suggest 
that a longer period of time pushes the digestion reaction to yield smaller peptides. In 
summary, we optimized the conditions for chymotrypsin digestion of recombinant human 
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histone H4 as 15 kpsi for 120 cycles. Each cycle was 1 min long and consisted of 50 s of 
high pressure and 10 s of atmospheric pressure. 
4.3.3 Summary of PCT using chymotrypsin 
Fig. 4.3 shows a representative spectrum of MALDI–TOF/TOF spectrometric analysis of 
fragments generated from chymotrypsin digestion of recombinant histone H4 using the 
optimal conditions established by this study. Table 4.3 shows sequences of peptides, 
which provide nearly complete sequence coverage. It is important to note that we were 
able to sequence the entire N-terminal end (histone tail) of histone H4. We also 
performed MS/MS analysis of five minor peaks with m/z 864.9, 1021.5, 1798.3, 2108.0, 
and 2331.1, but we were unable to assign them to any part of the histone H4 sequence, 
concluding that they are most likely part of contamination. 
4.3.4. RP–HPLC fractionation of intact histones 
After optimization of the PCT method using recombinant histone H4, we moved to the 
next step involving intact histones isolated from biological material. The source of 
histones used for this study was human monocytes obtained from elutriated blood of 
healthy donors (see Materials and methods). For preparation, histones were subjected 
to RP–HPLC fractionation (Fig. 4.4), followed by identification of collected fractions using 
MS. Histones H2B, H4, H2A, and H3 were eluted as separate peaks between 50 and 70 
min (Fig. 4.4 inset). Peaks appear to be broad, which is likely due to small differences in 
the elution time for post-translationally modified forms rather than due to 
chromatographic conditions. Histone H1 was eluted prior to the 50-min time point; 
however, it was not collected for the purpose of this study. A relatively broad fraction 
containing histone H4 was collected, as shown in the box in the Fig. 4.4 inset, and used 
for further experiments. 
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4.3.5. Chymotryptic digestion of native histone H4 using conventional and PCT 
methods 
Equal amounts of the HPLC fractions containing histone H4 were digested using 
either optimized PCT or the conventional method (i.e., atmospheric pressure). Peptides 
resulting from these digestions were analyzed using an LTQ-Orbitrap in a nanoLC–ESI– 
MS/MS configuration. The reason we used MALDI–TOF/TOF for digested recombinant 
histone H4 and used ESI–MS/MS for histone H4 purified from monocytes was because 
we expected a higher complexity in histone H4 from monocytes compared with the 
recombinant sample. Both digestion conditions yielded 75% sequence coverage (Fig. 
4.5), with 2SGRGKGGKGLGKGGAKRHRKVL23 being the only missing peptide. This was 
expected, to some extent, because the N-terminal tail of histone H4 is extensively post-






Table 4.1. Optimization of PCT pressure based on relative intensity of MALDI-









Table 4.3. Peptides generated using conventional chymotrypsin digestion of 





Figure 4.1. Pressure optimization for two peptides from the N-terminal tail portion 
of recombinant human histone H4. Pressure setting was varied for 10, 15, or 25 kpsi 





Figure 4.2. Time optimization for two peptides from the N-terminal tail portion of 
recombinant human histone H4. The amount of time the Barocylcer digested was 





Figure 4.3. MALDI–TOF mass spectrum of recombinant human histone H4 
digested using the PCT method. The numbered peaks match those generated by 
conventional chymotrypsin digestion, providing 95% sequence coverage, and are listed 





Figure 4.4. RP–HPLC chromatogram showing fractionation of histones using UV 
detector set at 214 nm. The inset shows an enlarged range of the peptides containing 





Figure 4.5. Comparison of peptide identification using digestion on high pressure 
and atmospheric (conventional) pressure. (A) conventional digestion; (B) histone H4 






The major advantage of the PCT method using the Barocycler NEP 2320 is that 
it significantly reduces the time necessary to proteolytically digest proteins. For example, 
using the PCT method, proteins can be digested in 120 min at 15 kpsi instead of 18 h at 
atmospheric pressure. It is important to note that our experimental approach focused on 
only one protein, and not additional proteins that are difficult for proteolytic digestion, 
thereby limiting the scope of this study. For example, this technology may be beneficial 
for tests involving highly glycosylated proteins such as mucins. Another limitation in our 
study is that the only proteolytic enzyme tested was chymotrypsin. Additional proteolytic 
enzymes are available and should be tested in the future.  
One observation from this study was that PCT using a Barocycler NEP 2320 
technology platform did not show a substantial qualitative difference between 10 and 15 
kpsi, and if based on peak intensity, 15 kpsi provided a more intact protein to be 
digested. However, there was a decrease in major peptides measured by peak intensity 
under 25 kpsi, which may indicate that proteolytic digestion was further forced at this 
pressure to yield smaller fragments. We find this phenomenon to be interesting for 
further explorations because it may be very useful in studies where the in-depth analysis 
of splice variants or isoforms is of interest. Overall, we conclude that PCT is a promising 
technique for more controlled sample preparation, as compared with arbitrary overnight 
incubation, and clearly reduces time for this step. However, additional efforts are needed 
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5.1. Summary and Conclusions 
We looked directly at the effects of Meth on a macrophage function, cytokine 
production, in macrophages and a possible mechanism for the observed effects. Our 
study was the first exploratory and most comprehensive study for measuring the levels 
of cytokines in Meth exposed macrophages over time and as a result, determined that 
Meth increases the production of more pro-inflammatory cytokines than anti-
inflammatory cytokines in the first few hours of administration. Cytokines play a large 
role in chemoattraction, proliferation, programmed cell death, cell phenotype switching, 
and regulation of inflammation. Further studies are needed to determine which of the 
cytokines expressed are secreted and the function they will have on surrounding target 
cells. However, it is clear that the dysregulation caused by Meth in the cytokines 
expressed in our study can have complex and numerous effects on other cell types and 
tissue. Another finding was that the cytokine changes are dynamic meaning they change 
based on concentration of Meth and time of exposure. One cytokine, in particular was 
strongly down-regulated, CCL7. The significance is CCL7 is it is critical for the clearance 
of cryptococcal neoformans, a fungal infection common in HIV-1 patients and Meth use 
exacerbates the pathogenesis. First, we investigated whether the silencing of CCL7 was 
due to DNA methylation but there was not a large enough increase that would yield gene 
repression. Therefore, we looked at which mechanisms induce CCL7 and found it is 
expressed by activation of TLR9 and accordingly, we explored the signaling pathway 
and the mediators that Meth might be altering to shift the expression. We measured by 
different means the levels of TLR9, IRAK, the activated state of IRAK, degradation of the 
inhibitory protein of NF-κB, IκB, and transcription factors such as STAT1, NF-κB, IRF7 
and phospho-IRF7. None of these factors seemed to change due to Meth exposure, at 
least not at the times we measured and under the conditions we measured. Additional 
and more thorough work needs to be done on how the signaling factors that mediate 
126 
 
TLR9 signaling change due to Meth. But in conclusion Meth affects cytokine production 
in macrophages and is mediated, at least in part, by TLR9 signaling.  
In the other study, we looked at HDAC1-6 and found that HDAC1 was 
significantly decreased in Meth exposed macrophages. There was a trend of decreased 
HDAC1 in HIV and HIV/Meth macrophages. The next step is to determine the effects of 
decreased HDAC1 on the functions of macrophages. Predictably, expression of viral 
loads would increase since HDAC1 is allows HIV to remain in a latent state [1]. 
Interestingly though, decreased HDAC1 in has been implicated in Meth-induced 
alterations of gene expression in the nucleus accumbens, a brain region responsible for 
feeling pleasure and reward, exacerbating addiction to Meth [2] These results suggest 
that the alterations in gene expression by HDAC1 can simultaneously worsen addiction 
and HIV infection. 
 
5.2. Challenges and Future Directions 
For our study we detected and measured levels of HDAC1 by three methods: 
densiometric quantification of immunoblots, qRT-PCR and confocal imaging. The 
biggest challenge came from quantitative Western blots of HDAC1. Despite including 
multiple donors, resulted in inconclusive data due to the large standard deviation 
preventing the statistical significance of the data. Although quantitative Western blots are 
common in the field, they are done improperly, regularly. Variability of densiometric 
analysis can be from differences in the most upstream step of processing cell cultures or 
lack of complete lysis of cells. Next, improper quantitation can result in differences due 
to the type of protein concentration method used for example: Pierce 660 versus 
Bradford versus absorbance at 280 nm, since each method exploits different properties 
of proteins. In conjunction with the protein concentration issue, is the oversaturation of a 
loading control like actin. Actin is so abundant in cells that it can easily reach the 
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detection limits of X-ray films and imaging softwares if loading more than 3 µg of cell 
lysate whereas, that amount is sometimes not enough to detect the protein of interest 
[3]. Other common loading controls like GAPDH are often used without first verifying that 
there is no effect on the expression with different treatments. Use of positive controls for 
Western blotting could significantly improve the quantitation for the protein of interest 
and a good positive control is a lysate that over expresses the gene interest. Incomplete 
separation of samples using SDS–PAGE usually comes from interfering reagents in the 
lysis buffer. To this end, there are commercial kits that remove the restricting chemical(s) 
but will most definitely cause a loss of proteins when purifying the sample. Thus, if 
blotting for more than one protein of interest with similar molecular weights one must 
decide if this cleaning up step is essential or overcome it by running two membranes, but 
both options result in loss or use of additional sample. Next, incomplete transfer of 
proteins to the PVDF membrane can occur to contribute to variations of densiometric 
analyses but the loss can easily be determined by staining the gel with Coomassie 
Brillant Blue. However, even if the step is not 100% efficient, Western blot is most likely 
not sensitive enough to detect the small difference in incomplete transfer of proteins. 
After transfer, membranes will be ready for primary antibodies but not all antibodies are 
not created equal thus giving rise to less than specific detection of the protein of interest 
and false positives or difficult time quantifying [4]. Running serial dilutions of the antibody 
control with different amounts of the positive control cell lysate can help you assess the 
quality of the antibody and can also prevent the oversaturation of the signal thus solving 
two problems at once. The issues mentioned were not known or foreseen when 
conducting the experiments and have taught me a lot. 
In conclusion, Western blots should be used only for the detection of proteins in a 
sample or used in a semi-quantitative manner meaning the only conclusion is less or 
more due to a treatment. The alternative and always better approach to Western blot is 
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an enzyme-linked immunosorbent assay (ELISA) for detection and quantification of 
proteins and with recent advanced can be multiplexed with decreased variability, higher 
reproducibility (intra-variability versus inter-variability), and increased confidence (or 
decrease in false positives). However, the price of ELISA is positively correlated to the 
number of proteins desired to be quantified. Future work should therefore always utilize 
ELISA for protein quantification when available, otherwise implement a positive control 
between donors, preferably more than three donors or replicates and a lysate of 
commercial grade so that quality control has been performed and reproducibility is 
similar between lots. Also, running a separate blot with far less protein loaded for actin 
normalization simultaneously with samples so variability due to the electrophoresis 
apparatus is minimized including separation of proteins and protein transfer to 
membranes. Finally, the antibody quality and optimized concentration should be 
determined before being used on the membranes by doing serial dilutions with the 
positive control samples. This ensures linearity of signal and prevention of signal 
saturation.  
Another challenge encountered with the conclusion of the Meth-induced up-
regulation of acetylation on H3 lysine 18 and H4 lysine 5 is related to quantitative 
Westerns since there was no normalization of PTMs to the total protein. Therefore, all 
histone blots should have been normalized to the corresponding unmodified histone 
otherwise, it is unknown whether Meth-induced an up-regulation of total histone or just 
the PTM.  
 Future directions should incorporate the use of chromatin immunoprecipitation 
with qPCR for both HDAC1 and specific histone acetylation sites to determine the genes 
affected by the absence of HDAC1 in Meth exposed macrophages and crossed 
referenced to the genes associated with the increase of acetylation due to Meth. This will 
identify genes linked to HDAC1 but more importantly, can use bioinformatics on the data 
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to understand how the genes correlate to function(s) of the macrophage that make it 
more susceptible to infections, which is the ultimate goal of the study. Further 
investigation needs to go into the trend of decreased HDAC1 in the HIV and HIV/Meth 
treatments that never reached statistical significance in our experiments but are 
confident from literature and our preliminary results that HDAC1 is involved in HIV 
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